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INTRODUCTION
The overwhelming majority of intellectual property (IP)
lawsuits settle before trial.'
These settlements involve
agreements between the patentee and the accused infringer,
parties who are often competitors before the lawsuit. Because
these competitors may agree to stop competing, to regulate the
price each charges, and to exchange information about products
and prices, settlements of IP disputes naturally raise antitrust
concerns.
In this Article, we suggest a way to reconcile the interests
of IP law and antitrust law in evaluating IP settlements. In
Part I, we provide background on the issue. Part II argues that
in most cases courts can determine the legality of a settlement
agreement without inquiring into the merits of the IP dispute
being settled, either because the settlement would be legal even
if the patent were invalid or not infringed, or because the
settlement would be illegal even if the patent were valid and
infringed. Only in a narrow class of cases will the merits of the
IP dispute matter. In Part III, we argue that, in that narrow
middle set of cases, antitrust's rule of reason is unlikely to be
helpful.
Rather, courts must inquire into the validity,
enforceability, and infringement issues in the underlying case,
with particular sensitivity to both the type of IP right at issue
and the industrial context of the dispute. In Part IV, we apply
our framework to a number of common settlement terms, most
notably the use of exclusion payments to settle pharmaceutical
patent disputes. We argue that exclusion payments that
exceed litigation costs should be presumptively illegal. There is
no legitimate reason for such payments, and the most likely
1. Mark A. Lemley, Rational Ignorance at the Patent Office, 95 NW. U. L.
REV. 1495, 1501 (2001).

2003]

ANTICOMPETITIVE SETTLEMENT

1721

reason-to permit the patentee to exclude competition that
would likely have occurred absent the payment-is
anticompetitive. Further, legitimate patent disputes can be
settled in other ways than with an exclusion payment-for
example, by licensing the defendant or by agreeing to delay
entry.
I. BASIC ISSUES AND CONFLICTS
Our legal system encourages firms to settle their disputes
out of court. 2 Settlements of IP disputes often take the form of
unrestricted or restricted licenses, which may or may not be
exclusive; cross-licensing arrangements; pools; agreements not
to license third parties or to license only jointly; or market
division or field-of-use agreements.3 Further, the agreements
are quite typically horizontal, particularly in patent cases, for
the firms are either actual or at least potential competitors in
the market for the ultimate product and may be competitors in
the innovation market itself. As a result, IP settlement
agreements raise significant antitrust issues. Indeed, some of
those agreements would be illegal per se if created in the
absence of a genuine IP dispute.4 Much of our legal doctrine
concerning the permissible scope of licensing agreements was
developed in cases in which the arrangements were undertaken
5
in settlement of an IP dispute.
2. Daniel A. Crane, Exit Payments in Settlement of Patent Infringement
Lawsuits: Antitrust Rules and Economic Implications, 54 FLA. L. REV. 747,
748 (2002).
3. For a general discussion of these licensing arrangements, see
HERBERT HOVENKAMP ET AL., IP AND ANTITRUST: AN ANALYSIS OF ANTITRUST
PRINCIPLES APPLIED TO INTELLECTUAL PROPERTY LAW (Supp. 2003).

4. See infra notes 25-38 and accompanying text.
5. E.g., United States v. Singer Mfg. Co., 374 U.S. 174, 196-97 (1963)
(disapproving of a settlement agreement that involved pooling plus exclusion);
United States v. New Wrinkle, 342 U.S. 371, 373-74 (1952) (involving crosslicensing with price restrictions); Hartford-Empire Co. v. United States, 323
U.S. 386, 400 (1945) (discussing horizontal customer restrictions); United
States v. Masonite Corp., 316 U.S. 265, 277 (1942) (involving a cross-license
with price restrictions); Standard Oil Co. (Ind.) v. United States, 283 U.S. 163,
169 (1931) (involving a patent pool); Noll v. O.M. Scott & Sons Co., 467 F.2d
295, 297 (6th Cir. 1972) (holding that a conveyance of a disputed patent to a
trustee who gave non-exclusive licenses to each party was not patent misuse);
Philip Morris v. Brown & Williamson Tobacco Corp., 641 F. Supp. 1438, 143892 (M.D. Ga. 1986) (discussing the legality of a cross-licensing agreement);
Duplan Corp. v. Deering Milliken, 444 F. Supp. 648, 683 (D.S.C. 1977), affd in
part, rev'd in part, 594 F.2d 979 (4th Cir. 1979); United States v. Huck Mfg.
Co., 227 F. Supp. 791, 797-98 (E.D. Mich. 1964) (involving a settlement that

1722

MINNESOTA LAW REVIEW

[Vol 87:1719

Assuming a genuine dispute, the outcome of a settlement
agreement that would otherwise produce an antitrust violation
might be no more anticompetitive than the outcome of
litigation. A judgment establishing the validity of a rival's
claim might prevent a competitor from entering a market
altogether, leaving the other with a monopoly. In such a case, a
settlement that excludes the competitor from the market would
not reduce competition that would otherwise legally exist, and
a settlement involving a license even on restrictive terms would
create more competition than if the IP owner had merely
enforced its rights to the fullest extent.
At the same time, the parties to an IP dispute have a
strong incentive to enter into agreements that maximize their
own interests but disserve the public's interest with respect to
either competition or innovation. Parties to an IP dispute, like
parties to a cartel agreement or joint venture, are more
interested in maximizing their own profits than enhancing the
public welfare. For this reason, judicial scrutiny of anticompetitive settlement agreements is appropriate, and harsher
scrutiny is appropriate when it appears clear that alternative,
less harmful settlement arrangements were available.
Incentives to collude are hardly reduced by the fact that a
dispute concerns IP. To the contrary, the uncertain scope and
validity of IP rights may encourage a collusive settlement,
serving both to remove the uncertainty and to permit the two
firms to share monopoly profits. For example, the owner of a
market-dominating patent 6 in infringement litigation will
continue to earn monopoly profits if it prevails but be no more
than one of many competitors if it loses. In such a case, a
settlement agreement that forms a cartel with the infringement
defendant may be the optimal choice for the parties. It will not
necessarily be optimal for society, however: Such collusion is
inefficient if there is any significant chance that the patentee
would have lost the suit.
Suppose that two horizontal competitors have developed
potentially conflicting patents for a superior computer memory
device. Each patent owner claims that the other's participation
in the market infringes on its patent. The parties commence
litigation but, contemplating a long and uncertain path, they
included cross-licensing with price restrictions), affd by an equally divided

Court, 382 U.S. 197 (1965).
6. As we have emphasized elsewhere, most patents do not in fact
dominate an economic market. See 1 HOVENKAMP ET AL., supra note 3, § 4.3.
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settle the dispute by agreeing to split the market: One will
manufacture its memory device for exclusive use by IBMcompatible computers, and the other will manufacture its
memory device exclusively for Apple computers. Formally, this
agreement may include a cross-license whereby each party
licenses to the other the right to use their patent within the
specified market segment.
This scenario poses a dilemma. Consider several factors.
First, in the absence of IP rights, the agreement in question
would be a per se unlawful market division. 7 Second, patent
litigation is extremely expensive and can lead to debilitating
uncertainty.8 As a result, settlement of private disputes is
generally cost reducing. Third, there may be doubt about the
validity or applicability of both patents-at least enough doubt
that each patentee might prefer to settle rather than litigate to
judgment. 9 Fourth, if the dispute were fully litigated, a court
might ultimately invalidate one firm's patent but uphold the
other, thus yielding the entire market to the other firm.
Alternatively, a court might conclude that both parties' patents
are valid and infringed, in which case neither party can sell in
the market. The proposed settlement is certainly no more
anticompetitive than either of those outcomes. Only if both
patents are held invalid or not infringed will the settlement
reduce competition.10 Finally, a less restrictive alternative is

7. Many criminal "price-fixing" cases in fact involve naked market
divisions. See, e.g., United States v. Brown, 936 F.2d 1042, 1044, 1050 (9th
Cir. 1991) (affirming a criminal conviction of rivals that divided the market for

billboard sites and agreed not to compete for each other's sites); United States
v. Suntar Roofing, 897 F.2d 469, 472 (10th Cir. 1990) (upholding a criminal
conviction for a horizontal customer allocation among roofers); see also 12
HERBERT HOVENKAMP, ANTITRUST LAW
2030 (1999) (noting that naked
market division agreements are unlawful per se and sometimes warrant

criminal sanction).
8. The median patent case that goes to trial costs each side $1.5 million
in legal fees, to say nothing of the costs to the company in lost employee time
and productivity. See Lemley, supra note 1, at 1502.

9. This factor should be taken with some caution. Because parties may
have more to gain by colluding than by competing on the merits, they may
have an incentive to settle even a case that the patentee is sure to lose. Thus,
it would be a mistake to infer from the fact that the parties settled that the

validity or scope of the patent was an open question.
10. The rather simple case we have posed assumes that the parties can
only compete using the patented technology. If one or both parties have

noninfringing alternatives, a settlement could be anticompetitive by leading
the parties to divide the market rather than to pursue (admittedly less
efficient) alternatives that would still create competition.
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also available: The parties could have cross-licensed the
patents without insisting on market division-an outcome that
would produce greater competition and would approximate the
competitive result in the absence of patent protection. "
Given these competing factors, courts have responded
leniently to settlements in which each party's claim seemed
reasonably legitimate but also seemed subject to a reasonable
risk of failure-that is, when the settlement appeared to be a
12
reasonable business decision and not a sham.
Antitrust challenges to IP disputes can be addressed either
on antitrust grounds or IP grounds. Few cases require courts
to balance the interests in the two statutes. In many cases
involving antitrust challenges to IP settlements, the presence
or absence of IP rights is largely irrelevant. In some situations,
the challenged practice is clearly not anticompetitive, and the
antitrust challenge can be dismissed without considering the
fact of an IP dispute and settlement. At the other extreme,
some
settlement
agreements
impose
anticompetitive
restrictions that cannot be justified by settlement of an IP
dispute, or that would unreasonably restrain competition even
assuming the IP rights in question were fully valid and
enforced. These restrictions should be unlawful regardless of
the legitimacy of the underlying IP right. Correctly placing
cases into one of these two classes is critical to rational
antitrust enforcement, because cases in the problematic middle
set are much more difficult to resolve.
This middle set of cases-where the agreement itself looks
like an antitrust violation but the presence of IP rights might
absolve it-is much more problematic and requires special
treatment. The traditional "rule of reason" analysis 13 is not a
good fit for practices that would be unlawful per se but for the
presence of an IP claim. The rule of reason is designed to
assess whether a practice tends to diminish market-wide
11.

Such a cross-license would, however, reduce the return to each party

on its patent.
12.

See, e.g., Standard Oil Co. (Ind.) v. United States, 283 U.S. 163, 171

(1931) (arguing that courts should encourage settlement of "legitimately
conflicting claims"); Boston Scientific Corp. v. Schneider (Eur.) AG, 983 F.
Supp. 245, 271 (D. Mass. 1997) (discussing a reasonable settlement that was
challenged by a competitor as a "concerted refusal[] to deal" (quoting SCM
Corp. v. Xerox Corp., 645 F.2d 1195, 1204 (2d Cir. 1981))). On the risk of
sham claims in a patent pool, see 2 HOVENKAMP ET AL., supra note 3, § 34.4al.
13. See infra note 24 and accompanying text (discussing "rule of reason"
analysis); infra note 25 (discussing "per se" analysis).
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output. 14 By contrast, the disputed issue in these middle cases
concerns the likely validity and scope of the claimed IP rights,
and the reasonableness of the settlement as one among many
outcomes of the IP dispute. That is, these cases should be
decided on IP grounds because the agreements in this middle
category are pro-competitive if, but only if, the patent in
question is valid and infringed. Antitrust's rule of reason
cannot help with that IP inquiry. All antitrust can do is
narrow the class of cases for which inquiry into the IP merits is
required.
II. DOES THE ANTITRUST INQUIRY DEPEND ON THE
PRESENCE OF AN IP DISPUTE?
When a court considers an antitrust challenge to an IP
settlement agreement, its first question should be whether the
IP dispute matters at all. The IP issues do not matter to
resolution of the case if (1) the agreement would be lawful
under the antitrust laws even in the absence of any IP dispute,
or (2) the agreement would be unlawful under the antitrust
laws even if all the IP claims that are made were fully
sustained.
Many settlements result in agreements that would not be
unlawful under the antitrust laws even if IP litigation was not
on the horizon. For example, two firms might challenge each
other's competing patents and resolve the litigation by giving
each other unrestricted, non-exclusive licenses. In that case,
the firms have done no more than agree to compete and not to
assert their IP rights against each other-an agreement that is
unlikely to reduce market-wide output or increase price even if
there had never been any IP rights in the first place. 15
Alternatively, a non-producing patentee like a research firm
might claim that a producer is infringing one of its patents, and
settle the dispute with an agreement permitting production for
a royalty. The agreement would be a purely vertical non-price
restraint. 16 As such, it would be analyzed under the rule of
14. See infra notes 24, 27 and accompanying text.
15. Courts may still want to inquire into the terms of the license,
however. Terms that restrict output under the cross-license, or that give each
party control over the downstream price set by the other, may have the effect
of encouraging or facilitating collusion. A royalty-free cross-license, on the
other hand, or a straightforward percentage-of-sales royalty to the patentee,
does not.
16. That is, although vertical "price" restraints are unlawful per se, the
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reason, and today almost all such agreements are lawful. 17 In
sum, a court can often resolve the antitrust challenge entirely
on antitrust grounds, without even considering the various
ways that IP rights affect the dispute.
At the opposite end of the scale, some agreements are
unlawful even if every IP right reasonably claimed in them is
both valid and infringed. For example, a settlement agreement
might include a horizontal market division that goes beyond
the scope of the disputed patent. Suppose that Ford claims
that a windshield wiper blade that Chevrolet is building and
installing on pickup trucks infringes a Ford patent. The
parties settle their dispute with an agreement that licenses the
blade to Chevrolet, but also restricts Ford to selling pickups
west of the Mississippi River and Chevrolet to selling east of
the river. That market division agreement would be unlawful
even if the windshield wiper blade patent was both valid and
infringed, because enforcing the patent would not prevent
Chevrolet from selling pickups. The court could dispose of the
antitrust issue without considering that the agreement settled
an IP claim. Once again, the dispute is resolved entirely on
antitrust grounds, for no patent policy is in conflict.' 8
Slicing off these two extremes still leaves us with the hard
cases, where the settlement agreement would constitute lawful
use of the claimed IP right if an infringement claim was valid,
but not if there were no valid IP right. Consider the case of socalled "blocking patents,"' 9 in which each party would have the
definition of such restraints is limited to situations in which the agreement
controls the resale price that the downstream firm must charge. See 8 PHILLIP

E. AREEDA, ANTITRUST LAw 1 1622 (1989). All vertical agreements of
necessity set a price for the transfer from the buyer to the seller.
17. On rule of reason treatment for vertical nonprice intra-brand
restraints and the resulting near universal legality, see HERBERT
HOVENKAMP, FEDERAL ANTITRUST POLICY § 11.6 (2d ed. 1999).
18. See, e.g., United States v. Singer Mfg. Co., 374 U.S. 174, 196-97 (1963)

(condemning a settlement agreement that involved cross-licensing and a
refusal to deal, even though the Court assumed that all the patents at issue
were valid).
19. On "blocking" patents and cross-licensing as a remedy, see 2
HOVENKAMP ET AL., supra note 3, §§ 34.2c, 34.4c. See also, e.g., Carpet
Seaming Tape Licensing Corp. v. Best Seam, Inc., 616 F.2d 1133, 1142 (9th
Cir. 1980) (discussing blocking patents); Mark A. Lemley, The Economics of
Improvement in Intellectual Property Law, 75 TEX. L. REV. 989, 1009-10
(1997); Robert P. Merges, Intellectual Property Rights and Bargaining
Breakdown: The Case of Blocking Patents, 62 TENN. L. REV. 75, 88 (1994);
Robert P. Merges & Richard R. Nelson, On the Complex Economics of Patent
Scope, 90 COLUM. L. REV. 839, 860-68 (1990).
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right to exclude the other from the market if the competing
patents are held valid. If the two patents are both valid and
indeed block each other, virtually any settlement into which
the parties enter concerning the patents will increase social
welfare, since at least one party acquires the right to sell the
product. On the other hand, if the patents are not valid or not
truly blocking, a settlement that restricts the parties from
competing will be anticompetitive. In these fact-dependent
cases, the general policy of the law has been to encourage
settlements, as the Supreme Court observed in Standard Oil
Co. (Indiana) v. United States20 and the federal government
echoed in its 1995 licensing guidelines. 2 1 As a result, some
agreements that would be unlawful if undertaken in the
absence of a reasonable dispute may be lawful when used to
22
settle a bona fide dispute.
The difficulty is that, under cover of a settlement
agreement, firms might engage in anticompetitive behaviorsuch as market division-that would be otherwise per se
unlawful. For that reason, once conduct is found that would
likely be an antitrust violation in the absence of a settlement,
some care must be taken to ensure (1) that the parties did have
a bona fide dispute, (2) that the settlement is a reasonable
accommodation, and (3) that the settlement is not more
anticompetitive than a likely outcome of the litigation. 23 In the
face of uncertainty, the antitrust tribunal must also consider
20.

283 U.S. 163, 171 (1931).
U.S. DEP'T OF JUSTICE & FED. TRADE COMM'N, ANTITRUST
GUIDELINES FOR THE LICENSING OF INTELLECTUAL PROPERTY § 5.5 (1995)
[hereinafter ANTITRUST GUIDELINES] ("Settlements involving the crosslicensing of intellectual property rights can be an efficient means to avoid

21.

litigation and, in general, courts favor such settlements."), http://www.
usdoj.gov/atr/public/guidelines/ipguide.pdf.
22. See, e.g., Carpet Seaming, 616 F.2d at 1142 (noting that a "wellrecognized legitimate purpose for a pooling agreement is exchange of blocking

patents").
23.

Carl

Shapiro

proposes

the

following test:

"that the

proposed

settlement generate at least as much surplus for consumers as they would
have enjoyed had the settlement not been reached and the dispute instead
been resolved through litigation." Carl Shapiro, Antitrust Limits to Patent
Settlements, 34 RAND J. ECON. (forthcoming 2003) (manuscript at 6, on file

with authors). Shapiro's test requires calculation of the odds of victory, the
effect of victory on competition, and the costs of litigation. See id. (manuscript
at 10, on file with authors).

Although we agree that this is the right basic

inquiry, as noted in text we would limit the inquiry to cases in which it is
unavoidable.

right metric.

Social rather than merely consumer surplus may also be the
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whether the parties might have settled on alternative, less
restrictive terms.
A court considering an antitrust challenge to an IP
settlement agreement should proceed in the following fashion.
First, it must ask whether the challenged settlement
agreement would have constituted an antitrust violation in the
absence of an IP controversy. If the answer is no, then the
antitrust challenge can be dismissed without further inquiry
into the effects of the IP dispute and settlement. If the answer
is yes, then the court should consider whether the challenged
settlement would be unlawful even if the IP rights claimed
were valid and infringed. If the answer to this second question
is again yes, then antitrust condemnation is in order without
regard to the presence of an IP dispute. Only cases that do not
fall within these camps must be decided on the basis of IP
policy rather than antitrust policy.
III. ANTITRUST'S RULE OF REASON AND
IP SETTLEMENTS
A. APPROPRIATE AND INAPPROPRIATE USES OF THE RULE OF
REASON

Antitrust generally applies the "rule of reason" to practices
that present some potential for competitive harm but also hold
out the promise of social gains. 24 Such practices cannot be
assessed without an inquiry into the defendant's individual or
collective market power and a determination of competitive
effects. Fundamentally, the antitrust tribunal wants to know
whether the challenged practice is likely to increase or decrease
market output. By contrast, antitrust applies the "per se rule"
when it has sufficient experience to conclude that a certain
class of practices is so likely to be anticompetitive without
offsetting social benefits that the much more expensive and
cumbersome analysis required by the rule of reason is
25
unnecessary.
Suppose that the settlement resolving an IP dispute

24.

The rule of reason requires courts to weigh the anticompetitive

consequences of a practice against its pro-competitive benefits. See 7 PHILLIP
E. AREEDA & HERBERT HOVENKAMP, ANTITRUST LAw IT 1507-1508 (2d ed.
2003).
25. Under the per se rule, a particular class of practices is declared illegal

without detailed inquiry into the merits of any given case. Id. %l 1509-1511.
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involves an agreement that would be per se unlawful in the
absence of the dispute. One might conceivably approach such
an agreement by saying that the presence of the IP settlement
is sufficiently mitigating so as to justify applying the more
lenient rule of reason. 26 We would avoid that approach as a
general proposition. The purpose of the rule of reason is to
determine whether, on balance, a practice is reasonably likely
to be anticompetitive or competitively harmless-that is,
whether it yields lower or higher market-wide output. 27 By
contrast, patent policy encompasses a set of judgments about
the proper tradeoff between competition and the incentive to
innovate over the long run. 28 Antitrust's rule of reason was not
designed for such judgments and is not adept at making them.
A properly defined per se rule represents a judicial judgment
that a particular restraint is so highly likely to be
anticompetitive-that is, output reducing and price increasing
in the short run-that a full inquiry into market power and
applicable defenses is not worth the court's trouble. 29 The
antitrust status of such agreements does not change merely
because the agreement arises in the context of an IP dispute.
The issue in such cases is not so much the economic
consequences of the agreement as whether those consequences
are deemed acceptable as a matter of IP policy.
For example, suppose that a patent settlement is resolved
with a GE-style price-restricted license. 30
Under the
settlement, GE, the patentee, licenses Westinghouse to make
light bulbs, but also stipulates the price at which Westinghouse
must sell these bulbs. In the absence of IP rights, this
agreement would be per se unlawful. 3 1 If the patent is valid
and infringed, however, the agreement would fall into the GE

26. See, e.g., Roger D. Blair & Thomas F. Cotter, Are Settlements of Patent
Disputes Illegal Per Se?, 47 ANTITRUST BULL. 491, 533-34 (2002) (advocating
this approach in part).
27. See supra note 14 and accompanying text.
28. See, e.g., ROBERT P. MERGES ET AL., INTELLECTUAL PROPERTY IN THE
NEW TECHNOLOGICAL AGE 13 (3d ed. 2003).
29. See 7 AREEDA & HOVENKAMP, supra note 24, $J 1509-1511.
30. In United States v. General Electric Co., the Supreme Court held that
a patentee could license a competitor subject to a restriction on the price the
competitor would charge for goods embodying the patent. 272 U.S. 476, 488
(1926). For a full discussion, see 2 HOVENKAMP ET AL., supra note 3, ch. 31.
31.

Price-fixing is illegal per se. See 9 AREEDA & HOVENKAMP, supra note

24, $ 1906.
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rule's antitrust exception for price-restricted licenses. 32
In such a case, applying the rule of reason to the
settlement agreement is unlikely to be helpful. Naked pricefixing is unlawful per se because judicial experience tells us
that price-fixing is so inherently anticompetitive that queries
into market power or competitive effects in a particular case
are not worth the added administrative costs. 33 Further,
rational parties engage in naked price-fixing only because they
presume they have at least some power to raise price above the
level that would prevail absent an agreement. 34 Those basic
facts do not change because the agreement at issue is termed a
settlement of an IP dispute. Rather, the incremental factual
issues to be resolved concern the questions whether the GE
patent is valid, whether Westinghouse's technology infringed,
and whether the license that results from the settlement goes
no further than GE would permit. 35 In short, the question is
whether this particular price-fixing agreement is one
contemplated by the IP laws as part of the supracompetitive
incentive those laws give to innovation. For these queries, the
burdens of production and proof properly rest with the
antitrust defendants (or proponents of the settlement) because
they typically control the information upon which resolution of
the infringement issue will be made.
As a second example, suppose that two competitors in a
patent dispute reach a horizontal territorial division
agreement. Under the settlement agreement the infringement
plaintiff gives the infringement defendant a license to practice
the disputed technology east of the Mississippi, while reserving
to itself the right to practice the technology west of the
Mississippi. There is no other integration of operations among
the firms, so this agreement would be a per se unlawful naked
territorial division in the absence of the IP dispute. 36 At the
same time, however, it would be a completely legal license of a
patent, because the Patent Act expressly provides that the
patentee may make territorially-restricted licenses. 37 The
antitrust rule of reason would require an assessment of market
32.
33.

See 2 HOVENKAMP ET AL., supra note 3, § 31.4.
See 11 HOVENKAMP, supra note 7, 1906.

34. Id.
35. There is also a legal question about the continued vitality of that
exception. See 2 HOVENKAMP ET AL., supra note 3, §§ 31.2-31.3.
36. See 12 HOVENKAMP, supra note 7, 2030b.
37. 35 U.S.C. § 261 (2000).
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power and the integrative potential of this market allocation
agreement. 38 But since the restraint is naked, application of
the rule of reason is not likely to tell us anything that we do not
already know. The additional issues added by the presence of
an IP dispute and settlement do not go to whether naked
horizontal agreements threaten competition. Instead, they go
to whether the agreement in question involved a legitimate IP
dispute, and whether the settlement at issue was a reasonable
accommodation given both the presence of IP rights and the
scope of their claims. In this particular case, these questions
are answered by the Patent Act, which expressly authorizes
naked horizontal territorial restrictions in patent licenses.
To be sure, there is one sense in which this might be
viewed as a rule of reason inquiry. Fundamentally, the rule of
reason considers whether a restraint is output increasing or
output decreasing. A naked territorial division agreement
between two competitors, neither of whom has the lawful power
to exclude the other, is output decreasing and thus unlawful.
By contrast, the licensing of a second producer by a firm whose
IP right does give it the power to exclude is presumptively
output increasing.3 9 Although the query formulated in this
fashion does appear to invoke the rule of reason, the content of
this rule really reduces to nothing more than the validity of the
underlying patent. So, we might say that, in the absence of a
valid infringement claim, the restraint is naked; but if the
infringement claim is valid, the restraint is ancillary.
This hardly means that the rule of reason has no place in
the analysis of antitrust challenges to IP settlements. Often
patent settlement agreements must be evaluated under the
rule of reason because they are ancillary to restraints involving
joint production. As a result, legality of the agreement vel non
must be established under the rule of reason quite aside from
any IP rights that might be involved. Generally, IP settlement
agreements qualify for rule of reason treatment when they
involve competitors but create only non-exclusive rights, 40 or
38.

Ancillary market division agreements are treated under the rule of

reason, but they require some element of joint production or distribution. See
13 HOVENKAMP, supra note 7,

2134.

39. See Polk Bros., Inc. v. Forest City Enters., 776 F.2d 185, 189-91 (7th
Cir. 1985) (applying this form of analysis to an ancillary output restraint); see
2030 (arguing that territorial market
also 12 HOVENKAMP, supra note 7,
division of patent rights is pro-competitive relative to the alternative of

refusing to license the right at all).
40. In general, non-exclusive rights permit production outside the scope of
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when they involve purely vertical agreements that do not
41
include per se unlawful resale price maintenance or bundling.
Finally, any antitrust rule must be sensitive to issues of
administrability and uncertainty. The costs of assessing the
validity of an IP claim may be significantly greater than the
costs of applying the rule of reason in some cases either
because the IP claim is difficult to assess or because the rule of
reason application seems reasonably easy. For example, in
some markets it will be clear upon a reasonably quick look that
the parties to the settlement agreement lack power in any
market. 42 In that case, dismissal of the antitrust complaint is
justified on antitrust grounds alone, without further inquiry
into IP policy. These cases may present the antitrust tribunal
with a choice: It can either analyze the restraint under the rule
of reason or else assume momentarily that the restraint is
unlawful and consider whether it is a valid settlement of a
legitimate IP dispute.
Courts should have considerable
discretion on summary judgment to dispose of a weak case on
the antitrust merits without getting to the underlying IP
43
issues.
44
A third example involves "blocking" patent claims.
Suppose that two makers of hard drives have potentially
blocking patent claims-that is, the practice of each patent by
its owner could constitute infringement of the other's patent.
The two firms settle their dispute by giving one another nonexclusive, unlimited cross-licenses. This agreement would have
to be analyzed under the rule of reason, but it is highly likely to

the agreement and thus cannot keep market output below the competitive
level, particularly if they include the right to sublicense. See 13 HOVENKAMP,
supra note 7, 2104.
41. For a discussion of why purely vertical arrangements such as resale
price maintenance and tying are said to be unlawful per se, see 8 AREEDA,
supra note 16, [ 1620-1627, and 9 id. I 1720. As we have noted elsewhere,
however, the prohibition on tying is not a per se rule in any meaningful sense.
1 HOVENKAMP ET AL., supra note 3, § 21.5d. Vertical nonprice restraints and
exclusive dealing are governed by the rule of reason. See 8 AREEDA, supra
note 16,
1645; 11 HOVENKAMP, supra note 7, 1820b.
42. See infra notes 119-27 and accompanying text (discussing how Clorox
Co. v. Sterling Winthrop, Inc., 117 F.3d 50 (2d Cir. 1997), serves as an example
of an agreement where the parties lacked market power).

43. See, e.g., Matsushita Elec. Indus. Corp. v. Zenith Radio Corp., 475
U.S. 574, 598 (1986) (rejecting an antitrust claim on summary judgment as
economically implausible).

44. See supra note 19 and accompanying text (introducing the concept of
"blocking" patents).
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be held "reasonable," and thus legal under the antitrust laws,
because it is non-exclusive and unlimited as to quantity, thus
giving the firms little opportunity for collusion. Further,
depending on market structure, the two firms may not control
enough of the market to make the restraint unlawful under the
rule of reason in any event.4 5 In this case, going directly to the
rule of reason antitrust analysis is likely to be a much simpler
way of resolving an antitrust challenge than the route of
assuming that the restraint is unlawful and considering
whether the conflicting patent claims are valid and
infringement is likely.
Other cases will be tougher-for example, where the
participants collectively dominate the market and the crosslicensing agreements contain quantity restrictions or market
divisions that make collusion more likely, or where settlement
agreements impose exclusive dealing under structural
conditions establishing prima facie illegality. 46 Suppose a nonproducing patentee such as an R&D firm settles its
infringement action against a producer with a territory- or
product-restricted license. For example, suppose that GE
makes no light bulbs itself, but simply develops and patents
light bulb technology. When Westinghouse makes bulbs
without obtaining a license, GE brings an infringement suit
that is settled by an agreement under which Westinghouse can
manufacture bulbs exclusively under the GE license
agreement.
In the absence of any IP rights at all, this particular
agreement would most closely resemble an exclusive dealing
agreement under which.a downstream manufacturer agrees to
use an upstream supplier's input exclusively.
Because
exclusive dealing is a rule of reason offense, the antitrust
challenger to this agreement would have to make out a
complete case under the rule of reason, including a market
definition and an assessment of the extent and duration of
market "foreclosure" under the criteria ordinarily applied in
rule of reason cases. 47 If the claim fails, the case is dismissed
entirely on antitrust grounds. If, however, the plaintiff makes
45. See Standard Oil Co. (Ind.) v. United States, 283 U.S. 163, 175-76
(1931) (applying the rule of reason and dismissing the complaint because the
owners of the potentially conflicting patents did not dominate the market).
46. On the structural conditions that make exclusive dealing unlawful,
see 11 HOVENKAMP, supra note 7, $ 1821.
47. See id.
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out a prima facie exclusive dealing case, then the burden shifts
to the defendant. 48 At that time the defendant may assert both
(1) the general defenses that arise in exclusive dealing claims 49
and (2) the additional considerations that might arise from the
presence of the IP right. In this case, proof of (2) would require
a showing of likely validity and infringement of GE's patent.
Significantly, proof of (2) would be unnecessary if the ordinary
antitrust criteria for assessing exclusive dealing showed no
illegality in the first place.

B. VALIDITY OF IP CLAIMS; REASONABLENESS OF SETTLEMENT
TERMS
Once a settlement appears to be unlawful under either the
per se rule or the rule of reason, the agreement's special status
as resolution of an IP dispute becomes relevant. Under our
approach, such an agreement can be saved from antitrust
condemnation if two things are true. First, there must have
been a legitimate dispute concerning an IP right and likely
infringement of a valid IP right. Second, the settlement
agreement must be within the range of likely outcomes of
litigation, or no more anticompetitive than such an outcome
would have been. Unfortunately, these inquiries may be the
very ones that the settlement agreement itself sought to
forestall because of their complexity and uncertainty. That is
why it is critical that these inquiries be made no more often
than necessary.
The Patent Act requires settlements in one particular type
of patent dispute-interference cases-to be filed with the
PTO. 50 While filing might draw the attention of government
enforcers to such agreements, it protects against the collusive
settling of frivolous patent claims only if the PTO were to make
a determination whether the patents at issue in the lawsuit
were likely valid and infringed. The PTO never makes such
determinations, although it does make copies of filed
48. Id. 1822.
49. Id.
50. See 35 U.S.C. § 135(c) (2000); CTS Corp. v. Piher Int'l Corp., 727 F.2d
1550, 1555 (Fed. Cir. 1984) (suggesting that § 135(c) was designed to prevent
the use of anticompetitive settlement agreements); United States v. FMC
Corp., 717 F.2d 775, 777-78 (3d Cir. 1983) (same); Moog, Inc. v. Pegasus Labs.,
Inc., 521 F.2d 501, 505 (6th Cir. 1975) (same); see also Precision Instrument
Mfg. Co. v. Auto. Maint. Mach. Co., 324 U.S. 806, 818 (1945) (refusing to
enforce a filed settlement that did not reveal possible perjury in connection
with the application for a related patent).
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5
settlements available to the FTC. '
There is also some precedent for judicial inquiry into the
soundness of settled patent claims. In Standard Oil, the
Supreme Court approved the appointment of a special master
to determine whether the patents held by the various parties
were sufficiently broad to warrant a conclusion that they
interfered with one another. 52 And in United States v. Singer
Manufacturing Co., the record suggested that the parties had
reached a settlement in part in order to avoid drawing
attention to prior art that might have resulted in the
53
invalidation of several of their patents.
Permitting ex post judicial queries into the validity and
coverage of settled patents may sound onerous, and may
sometimes even be a deal breaker. But it is necessary in our
"middle set" of cases in order to distinguish pro- from
anticompetitive agreements. Requiring scrutiny of the merits
of a patent case can also serve the useful purpose of
encouraging the parties to execute a less restrictive settlement
agreement where such an alternative is available.
For
example, infringement actions against competitors can be
settled either by a license permitting production by the
licensee, perhaps with royalty payments to the patentee
(output increasing and likely pro-competitive), or by payments
to the infringement defendant for its exit from the market
(highly suspicious). 54 If there is considerable uncertainty about
the validity or coverage of the patent, requiring an evaluation
of the patent merits will encourage firms to take the former
course rather than the latter.

51. In the late 1990s, Joel Klein, then-assistant attorney general for
antitrust enforcement, proposed that cross-licenses be filed with the antitrust
authorities to permit a quick, Hart-Scott-Rodino-style review. Joel I. Klein,
Cross-Licensing and Antitrust Law, Address Before the American Intellectual
Property Law Association (May 2, 1997), at http://www.usdoj.govatr/public/speeches/1123.htm (last visited Mar. 6, 2003). Section 135(c)
already gives such a power, but only in the subset of interference disputes that
are actually litigated and then settled. See 35 U.S.C. § 135(c). For an
argument in favor of an expanded obligation to disclose patent settlement
agreements, see Maureen A. O'Rourke & Joseph F. Brodley, An Incentives
Approach to Patent Settlements: A Commentary on Hovenkamp, Janis &
Lemley, 87 MINN. L. REV. 1767, 1775-76 (2003).
52. Standard Oil Co. (Ind.) v. United States, 283 U.S. 163, 180-81 (1931).
53. 374 U.S. 174, 199 (1963). The Court assumed that the patents were
valid but condemned the restraint anyway. Id.
54. See infra notes 130-84 and accompanying text.
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IP SErLEMENTS
The middle set of cases, in which the IP owner's likelihood
of success on the merits of the underlying lawsuit will
determine whether the settlement is pro- or anticompetitive, is
not a random sample of all possible IP cases. We can make two
predictions about where such cases are likely to occur. First,
patent cases are more likely than copyright cases to fall within
the middle category. Second, settlement of patent disputes in
some industries is more likely to be pro-competitive than in
other industries.
C. INDUSTRY-SPECIFIC NATURE OF

1. Comparing Patent Disputes to Copyright Disputes
Patent disputes frequently occur between horizontal
competitors. Because those competitors are usually making the
same or similar products, a settlement that prevents one of
them from participating in the market is likely to have some
sort of competitive effect. Further, because patents may cover
components of a product, rather than actual commercial
products, and because copying is not an element of a case for
patent infringement, patentees often find themselves the
owners of patents that block each other. 55 These blocking
patent rights must be cleared in order for some or all of the
owners to sell an integrated product. 56 If the parties do not
come to terms, and the patents are found valid and infringed,
none of the parties may be able to sell the product. 57 A variety
of private agreements, from simple cross-licenses to standardsetting organizations' rules to complex patent pools, exist to
clear these rights. 58 Whether these horizontal agreements
between competitors are pro- or anticompetitive will frequently
depend on whether the parties could have competed without
the arrangement, and therefore on whether the underlying
59
patents were valid and infringed.
Several characteristics of copyrights make similar cases
unlikely. First, copyrights are often enforced not against
55. See supra note 19 and accompanying text.
56. See Merges & Nelson, supra note 19, at 860-61.
57. See id.
58. See, e.g., Mark A. Lemley, Intellectual PropertyRights and StandardSetting Organizations,90 CAL. L. REV. 1889, 1892-95 (2002) (standard-setting
organizations); Robert P. Merges, Contractinginto Liability Rules: Intellectual
Property Rights and Collective Rights Organizations, 84 CAL. L. REV. 1293,
1340-58 (1996) (patent pools).
59. See supra notes 10-11 and accompanying text.
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competing creators, but against those who would be buyers but
for their infringement.
The antitrust risks of vertical
agreements are significantly less than the risks of horizontal
agreements. 60
Second, unlike patents, copyrights can be
infringed only when a defendant copies the plaintiffs' work.6 1
Although it is possible that two copyright owners will each
claim that the other copied certain material from it, such
symmetrical claims are much less likely than in patent cases.
As a result, there is no corollary in copyright law to this
important class of patent disputes that require investigation of
the merits. 62 Where blocking copyright cases do arise, the legal
outcome is different because there is no law of "blocking
copyrights." 63
Rather, the creator of a work that uses
infringing material from another loses all copyright in the
newly created work.64 An important justification for patent
cross-licenses thus disappears in the copyright context; the
original creator will be free to use his own work and indeed
even his rival's new material without liability.65 The (rare)
60. While there are often horizontal agreements between copyright
owners, they tend to be not settlements of cases but agreements to bring
lawsuits jointly or agreements to license defendants only on certain terms.
These agreements can be anticompetitive, but it is not the settlement of the
copyright suit that creates the antitrust problem. See Primetime 24 Joint
Venture v. Nat'l Broad. Co., 219 F.3d 92, 99 (2d Cir. 2000); cf. Broad. Music,
Inc. v. Columbia Broad. Sys., Inc., 441 U.S. 1, 24 (1979). For a discussion of
the antitrust issues that arise in such a case, see 2 HOVENKAMP ET AL., supra
note 3, § 35.6b.
61. Sheldon v. Metro-Goldwyn Pictures Corp., 81 F.2d 49, 54 (2d Cir.
1936) ("[11f by some magic a man who had never known it were to compose
anew Keats's Ode on a Grecian Urn, he would be an 'author,' and, if he
copyrighted it, others might not copy that poem, though they might of course
copy Keats's.").
62. This is not to suggest that antitrust cases never arise that require
courts to determine the scope of a copyright. In United States v. Microsoft
Corp., the court evaluated the government's claim that Microsoft unilaterally
imposed unreasonable restrictions on licensees in part by determining
whether copyright law did in fact give Microsoft the power to prevent the
modifications the licensees sought. See 253 F.3d 34, 60-62 (D.C. Cir. 2001),
cert. denied, 534 U.S. 952 (2001).
63. See Lemley, supra note 19, at 1021.
64. See 17 U.S.C. § 103(a) (2000). Strictly speaking, the creator of the
derivative work loses only rights in any part of the new material in which
unlawful material is used. Id.
So, if the work is composed of discrete
segments, she may be able to retain some copyright. See Lemley, supra note
19, at 1022.
65. See Anderson v. Stallone, 11 U.S.P.Q.2d 1161, 1173-74 (C.D. Cal.
1989) (holding that Stallone was free to copy elements from Anderson's
unauthorized script for Rocky IV because Anderson infringed the copyright in
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settlements of copyright disputes that restrict the ability of
both parties to sell in a market may therefore be approached
with more skepticism than would analogous patent settlements.
2. Patent Disputes in Various Industries
Economic evidence strongly suggests that the patent
66 Of
system has very different effects in different industries.
particular interest for our purposes, there is tremendous
variance by industry in the effective scope of the patents that
issue. 67 This variance results from the relationship between a
patent and a product. 68 In some industries, such as chemistry
and pharmaceuticals, a single patent normally covers a single
product. 69 The patent system is built on the unstated
assumption of this one-to-one correspondence. 70 We speak of
patents covering products, measuring damages by the profits
lost in the sale of infringing products, and the like. 71 In fact,
however, such a correspondence is the exception rather than
the rule. 72
Machines of even moderate complexity are
composed of many different pieces, and each of these
73
components can itself be the subject of one or more patents.
No inventor could patent a modern car, for instance. Rather,
they will patent a particular invention-say, intermittent
windshield wipers-that is only one small piece of a much
larger product. 74 In industries like semiconductors, new
products are so complex that they can incorporate hundreds
and even thousands of different inventions, inventions
frequently patented by different companies. 75
A patent
covering one of those hundreds of components won't effectively
the previous Rocky character).
66. See, e.g., Dan L. Burk & Mark A. Lemley, Policy Levers in Patent Law,
89 VA. L. REV. (forthcoming Dec. 2003) (manuscript at 13, on file with

authors).
67.

See id.

68. Id. at 15.
69. Id.
70.
71.
72.
73.
74.

Id.
Id.
Id.
Id.
See Kearns v. Gen. Motors Corp., 152 F.3d 945 (Fed. Cir. 1998)

(unpublished table decision) (involving a patent dispute over intermittent
windshield wipers).
75.

Burk & Lemley, supra note 66, at 16.
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protect a product; it is useful, if at all, only as a licensing tool. 76
The relationship -between a patent and a product
determines the likelihood of - blocking patent claims, and
therefore the need for settlements or ex ante agreements to
resolve those blocks. No one can build a new microprocessor
without running afoul of hundreds of patents owned by
competitors. Innovation in the semiconductor industry would
cease if patent owners could not cross-license their patents. By
contrast, virtually no pharmaceutical patents are truly
blocking; pharmaceutical patents tend to issue for drugs that
can themelves be sold as products. This doesn't mean that
settlements between competitors are never anticompetitive in
the semiconductor industry, or that they are always
anticompetitive in the pharmaceutical industry. But it does
mean that one important pro-competitive justification for
settlement agreements-the desire to clear blocking patentsis much more plausible in semiconductors than in
pharmaceuticals. The same point can be extended to other
industries as well. 77 Antitrust courts and agencies should take
the characteristics of the industry into account in assessing
such settlement agreements.
IV. PARTICULAR SETTLEMENT PROVISIONS
In this Part we classify the various types of settlement
provisions, ranking them very roughly from those that pose the
least antitrust risk to those that pose the greatest. Settlement
agreements are often complex documents, and many will
include provisions of more than one type.
A. NON-EXCLUSIVE, UNRESTRICTED LICENSES IN FAVOR OF
ALLEGED INFRINGERS; NON-EXCLUSIVE CROSS-LICENSES

The simplest situations posing the least risk of competitive
harm are those in which a patentee sues a rival or potential
rival for infringement, and the plaintiff settles by giving the
defendant a non-exclusive license to practice the patent in
exchange for royalties or other consideration. The granting of a
non-exclusive license itself almost never harms competition,
regardless of the presence or absence of any IP dispute. A non76. Id.
77. For example, standard-setting organizations in the Internet and
telecommunications industries often endeavor to clear potentially blocking
royalty positions. See Lemley, supra note 58, at 1948-54.
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exclusive license does not restrain the patentee's ability to
produce patented goods itself or to license others in the future.
Also, the non-exclusive license' itself adds at least one new
producer to the market. 78 Antitrust challenges to such
settlements can usually be dismissed, purely on antitrust
grounds, without any inquiry into IP issues.
Where there are antitrust concerns in such non-exclusive
license settlements, they generally involve not the fact or
nature of the license but other restrictions imposed on the
licensee. We have already discussed one such problem above: a
license agreement that limits the licensee's behavior in a
broader market than the patent covers. 79 Other terms that
raise antitrust issues might include a requirement that the
80
licensee pay royalties even on goods not covered by the patent
or, in unusual circumstances, a reciprocal licensing
requirement. 81 The restrictions in these cases present antitrust
concerns for reasons unrelated to the existence of the IP right
in suit. It is the patentee's attempt to impose restrictions on
the licensee beyond the scope of the patent-presumably in lieu
of monetary royalties-that raises competitive concerns. Thus,
these restrictions can be judged under existing principles of
antitrust law without worrying about the strength of the patent
claims.

78. Boston Scientific Corp. v. Schneider (Eur.) AG, 983 F. Supp. 245, 271
(D. Mass. 1997) (distinguishing a situation in which a firm agrees with

another not to license its own patent from one in which it agrees not to license
a patent that it has licensed from others, and upholding the cross-licensing
agreement), appeal dismissed, 152 F.3d 947 (Fed. Cir. 1998); cf. Int'l Mfg. Co.

v. Landon, Inc., 336 F.2d 723, 730 (9th Cir. 1964) (upholding an agreement
that required two owners of patents likely to block each other to license others
only jointly but placed no restrictions on the number of licenses they could
issue).
79. See supra p.1726 (providing a hypothetical example of such an
agreement involving Ford and Chevrolet).
80. See 1 HOVENKAMP ET AL., supra note 3, § 3.3b2.

81. In re Intel Corp., Analysis of Proposed Consent Order to Aid Public
Comment, F.T.C. Dock. No. 9288 (Mar. 17, 1999), http://www.ftc.gov/
os/1999/9903/d09288intelanalysis.htm. The FTC challenged such a reciprocal
licensing requirement and Intel agreed in a consent decree not to require those

who dealt with it to give up all patent claims against Intel. Id. But see
Intergraph Corp. v. Intel Corp., 195 F.3d 1346, 1367 (Fed. Cir. 1999) (rejecting

an antitrust claim based on Intel's reciprocal dealing). For a more detailed
discussion of the economics of such a claim, see 1 HOVENKAMP ET AL., supra
note 3, § 13.4d.
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B. PURELY VERTICAL AGREEMENTS
When the infringement plaintiff and defendant are not
actual or potential rivals in any market, a settlement
agreement among them rarely raises antitrust concerns. 82 For
example, the infringement plaintiff may be a seller of some
product or input, and the infringement defendant may be no
83
more than a purchaser.
An occasional purely vertical agreement might raise
concerns about resale price maintenance, tying, or exclusive
dealing. For example, a manufacturing infringement defendant might settle a dispute by agreeing to sell the product
manufactured under the settlement agreement at a price set by
the non-manufacturing patentee. 84 Alternatively, an infringement defendant using the patentee's technology in its own
production process might settle an infringement suit by
agreeing to use exclusively technology licensed from the
patentee.8 5 Or, an infringement defendant might agree to an
arrangement in which it agrees to accept some undesired
technology or to purchase some undesired product from the
infringement plaintiff in exchange for the right to obtain a
license for the desired product.8 6 Package licenses fall into this
latter category. A research firm might license its patents only
87
in packages, typically in order to reduce monitoring costs.
In all such cases the presence of an IP dispute settled by
the agreement in question should have little bearing on its
82. E.g., United States v. Studiengesellschaft Kohle, 670 F.2d 1122, 1138
(D.C. Cir. 1981) (upholding purely vertical restraints that resulted from a
settlement agreement involving an owner of a process patent and various
producer licensees).
83. Id.
84. E.g., Bement v. Nat'l Harrow Co., 186 U.S. 70, 94 (1902) (approving a
settlement agreement that permitted the infringement defendant to
manufacture agricultural harrows using patents owned by the infringement
plaintiff, at a royalty of $1.00 per harrow, and to be sold at prices stipulated by
the infringement plaintiff).
85. Bement also involved a promise by the licensee that it would not
manufacture harrows employing any technology other than that licensed by
the infringement plaintiff. Id. at 73.

86. See, e.g., Int'l Salt Co. v. United States, 332 U.S. 392, 400 (1947)
(invalidating a tying arrangement in which a licensee of a patented salt lixator
agreed to purchase salt only from the patentee).

87. E.g., Automatic Radio Mfg. Co. v. Hazeltine Research, Inc., 339 U.S.
827, 836 (1950) (permitting package licensing of patents to which the licensee
voluntarily agreed). On package licensing as a mechanism for reducing
monitoring costs, see 1 HOVENKAMP ET AL., supra note 3, § 22.5d.
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antitrust legality. Resale price maintenance, exclusive dealing,
and tying are usually governed by ordinary antitrust principles
when any IP rights that are involved are not in dispute. The
outcome is generally no different when a dispute is present.
For example, resale price maintenance is unlawful whether or
not the patent is valid, unless it is protected by the narrow
88
exception created in GE.
The tying situation is more complex. A "hard core" tie of
patented and non-patented products remains unlawful aside
from questions about patent validity. Indeed, the proscription
of tying in section 3 of the Clayton Act applies to goods
"whether patented or unpatented. ''89 In the case of "pure" IP
ties-where both the tying and tied product are IP rights-the
courts have behaved much more erratically. "Block booking" of
motion pictures and television shows remains per se illegal, 90
while package licensing of patents 9' and blanket licensing of
copyrighted works 92 are generally treated under the rule of
reason. But, in all events, where the plaintiff and defendant
are not competitors, competitive harm is unlikely unless the
bundling of rights threatens significant foreclosure of
competing IP rights. Very few cases have found a foreclosure
93
threat.
88.

See 1 HOVENKAMP ET AL., supra note 3, § 24.1b (noting that the courts

have tended to apply the GE price-fixing exception to both vertical and
horizontal agreements). For further discussion of the GE rule, see supra notes
30-35 and accompanying text.
89. 15 U.S.C. § 14 (2000).

90. See, e.g., United States v. Loew's, Inc., 371 U.S. 38, 55 (1962) (holding
block booking illegal); United States v. Paramount Pictures, Inc., 334 U.S. 131,
156-59 (1948) (same); MCA Television Ltd. v. Pub. Interest Corp., 171 F.3d
1265, 1280 (l1th Cir. 1999) (same); see also 1 HOVENKAMP ET AL., supra note
3, § 22.5a.

91. E.g., Automatic Radio Mfg., 339 U.S. at 831.
92. E.g., Broad. Music, Inc. v. Columbia Broad. Sys., Inc., 441 U.S. 1, 9
(1979) (holding that collective licensing of copyrights by a collective licensing
organization was not illegal per se); Broad. Music, Inc. v. Moor-Law, Inc., 527
F. Supp. 758, 767-68 (D. Del. 1981) (refusing to require the defendant to break
down its blanket license of copyrighted songs into smaller categories), affd,
691 F.2d 490 (3d Cir. 1982) (unpublished table decision), affd sub. nom. In re

Moor-Law, Inc., 691 F.2d 491 (3d Cir. 1982) (unpublished table decision).
93. One possible exception is Grid Systems Corp. v. Texas Instruments,
which included a claim that a package license from the licensor had the effect
of discouraging the licensee from licensing patents from another. 771 F. Supp.
1033, 1038 (N.D. Cal. 1991). Perhaps the most important example is United
States v. Microsoft Corp., 253 F.3d 34, 64 (D.C. Cir. 2001), cert. denied, 534
U.S. 952 (2001). See Herbert Hovenkamp, IP Ties and Microsoft's Rule of
Reason, 47 ANTITRUST BULL. 369, 373 (2002).
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In sum, the great majority of challenges to purely vertical
agreements settling infringement actions-though not all-can
be resolved entirely on the basis of antitrust analysis, with no
inquiry into the validity of the underlying infringement
94
claims.
C. EXCLUSIVE LICENSES TO ALLEGED INFRINGERS; EXCLUSIVE
CROSS-LICENSES AND POOLS; CONCERTED REFUSALS TO DEAL

Suppose the patentee sues an infringer and settles with an
agreement that licenses the infringement defendant to practice
the patent, but also promises that no one other than the
patentee or this licensee will ever be licensed. Assuming the
patent is valid, the Patent Act expressly permits exclusive
licenses, 95 but it seems clear that that fact alone does not
96
render them immune from antitrust scrutiny.
The inquiry into the validity of the infringement claim is
necessary only if the settlement agreement itself poses an
antitrust threat.97 The antitrust risks resulting from exclusive
rights can be more substantial than those involving nonexclusive licenses. 98 If the settlement involves nothing more
than an exclusive license from the infringement plaintiff to the
infringement defendant without price, quantity or market
segment restrictions, the antitrust risks are reasonably small.
The mere payment of money from the defendant to the plaintiff
does not create an antitrust problem, and would certainly be
lawful if the patent is valid and infringed. If the patent is
invalid, then the agreement does not necessarily exclude
anyone, for others will be able to challenge the patent as well. 99
94. See Hovenkamp, supra note 93, at 372.
95. 35 U.S.C. § 261 (2000).
96. 1 HOVENKAMP ET AL., supra note 3, § 14.2bl. Among other antitrust
statutes, section 7 of the Clayton Act, 15 U.S.C. § 18 (2000), has been applied
to exclusive patent licenses that tend to overly concentrate a market. 1
HOVENKAMP ET AL., supra note 3, § 14.2bl.
97.

See 1 HOVENKAMP ET AL., supra note 3, § 14.2bl.

98. See id.
99. There is some risk that a patentee may seek to insulate its patent
from antitrust challenge by co-opting the most likely challengers with licenses.
Where co-option is a problem, the antitrust risks of a settlement are greater
than where other potential defendants are likely to challenge the validity of a
patent. The Supreme Court significantly reduced that risk in Lear, Inc. v.
Adkins by permitting licensees to challenge the validity of the patents they
license. 395 U.S. 653, 676 (1969). The Federal Circuit has chipped away at
that rule, however. See Studiengesellschaft Kohle, M.B.H. v. Shell Oil Co.,
112 F.3d 1561, 1568 (Fed. Cir. 1997) (requiring the payment of royalties by a
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The same thing is generally true of an exclusive crosslicense resolving conflicting patent claims. The two parties
might license only each other to practice their respective
patents. But if the patents are invalid in any event, then third
parties are not really being excluded, since they can simply use
the patented technology without fear of liability. 100 If the crosslicenses do not include price, quantity, or market division
provisions, then collusion in the production of downstream
products may not be a particularly great risk. 01 By contrast,
cross-licenses that involve payments by one or both parties
necessitate the exchange of price and output information
between competitors, and can therefore facilitate coordinated
output restrictions.
These agreements may be perfectly
legitimate, and indeed are generally pro-competitive where the
parties hold actual or plausible blocking patents. 10 2 But they
licensee who successfully challenges the validity of a patent up until the day
the patent is challenged). In any event, the law does not permit a licensee who
once challenged a patent's validity and settled that lawsuit to reopen the
challenge. For a more thorough discussion of the cases, and an argument that
even settlements should not necessarily bar validity challenges by licensees,
see O'Rourke & Brodley, supra note 51, at 1778-81. But see generally Rochelle
Cooper Dreyfuss, Dethroning Lear: Licensee Estoppel and the Incentive to
Innovate, 72 VA. L. REV. 677 (1986) (challenging Lear's rationale).
100. The greater the number of patents that are involved, however, the
greater the cost and risk in determining that they are invalid and deciding to
infringe them. So, the principle stated in the text has limits, especially where
many different parties enter into a group cross-license that excludes others.
101. See Standard Oil Co. (Ind.) v. United States, 283 U.S. 163, 183 (1931)
(upholding a patent pool); Carpet Seaming Tape Licensing Corp. v. Best Seam,
Inc., 694 F.2d 570, 579-80 (9th Cir. 1982) (permitting a settlement agreement
that required mandatory package licensing of allegedly blocking patents after
several years of actual patent litigation, and reversing the district court
decision that rejected the agreement on the theory that mutual non-exclusive
licenses would have been less anticompetitive); Philip Morris, Inc. v. Brown &
Williamson Tobacco Corp., 641 F. Supp. 1438, 1491 (M.D. Ga. 1986)
(upholding exclusive cross-licensing). To be sure, because the parties are
dealing together already, any possible cartel is easier for them to arrange.
Where the deal is a simple royalty-free cross-license, however, it may not
require that much ongoing interaction.
102. Carpet Seaming, 616 F.2d at 1142 (concluding that legitimately
blocking patents justify cross-licensing arrangements). Commentators have
discussed the antitrust treatment of patent pools. See, e.g., 1 HOVENKAMP ET
AL., supra note 3, §§ 34.1-34.4cl; Roger B. Andewelt, Analysis of Patent Pools
Under the Antitrust Laws, 53 ANTITRUST L.J. 611, 611-39 (1984); John H.
Barton, Patents and Antitrust: A Rethinking in Light of Patent Breadth and
Sequential Innovation, 65 ANTITRUST L.J. 449, 462-65 (1997); Steven C.
Carlson, Patent Pools and the Antitrust Dilemma, 16 YALE J. ON REG. 359,
361-99 (1999); Richard J. Gilbert, Patent Pools: 100 Years of Law and
Economic Solitude (May 5, 2002) (unpublished manuscript, on file with
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may also be shams designed to give legal cover to a cartel. 01 3
A concerted refusal to deal with third parties that goes
beyond exclusive cross-licensing might raise serious antitrust
issues, but analysis of the competitive harm generally will not
depend on underlying IP issues. 10 4 For example, conflicting
claimants might license one another exclusively but also agree
not to sell some essential input to third parties. The latter
agreement would ordinarily be unlawful per se quite aside from
105
the validity of the patent infringement claims.
The IP laws do not protect promises limiting the licensing
of subsequently developed technology at all, because their
subject matter is not an existing IP right.10 6 For example,
while the Patent Act permits price and territorial restraints in
licensing agreements covering existing patents, an agreement
to place the same limitations on patents to be developed in the
future raises no patent law issue. 10 7 Of course, this does not
mean that restraints on subsequently developed technology are
unlawful per se. Many are perfectly valid ancillary restraints.
The clearest example is grantbacks, which are promises by the
licensee to license future technology to the patentee, either
exclusively or non-exclusively.10 8 Non-exclusive grantbacks can
serve the legitimate purpose of ensuring that the original
patentee does not find itself excluded from the market by
licensees that patent improvements on the patentee's original
idea. 10 9 Exclusive grantbacks and requirements that a licensee
assign the rights to improvements to the original patentee are
more troubling, since they reduce or eliminate a licensee's
authors); Josh Lerner & Jean Tirole, Efficient Patent Pools (2002)
(unpublished manuscript, on file with authors).
103. See Andewelt, supra note 102, at 623-28.
104. See id. at 618.
105. E.g., United States v. Singer Mfg. Co., 374 U.S. 174, 196-97 (1963)
(disapproving a settlement agreement that involved pooling plus exclusion
even though the Court expressly assumed that the patents at issue were
valid); see also AG Fur Industrielle Elektronik Agie v. Sodick Co., No. 87 C
8974, 1990 WL 174921, at *3-*4 (N.D. Ill. Oct. 22, 1990); cf. Duplan Corp. v.
Deering Milliken, Inc., 444 F. Supp. 648, 683 (D.S.C. 1977) (construing a crosslicensing agreement as a concerted refusal to deal), affd, 594 F.2d 979, 981
(4th Cir. 1979).
106. 1 HOVENKAMPETAL., supra note 3, § 25.1.
107. 35 U.S.C. § 261 (2000).
108. See 1 HOVENKAMP ET AL., supra note 3, §§ 25.2-25.3.
109. Transparent-Wrap Mach. Corp. v. Stokes & Smith Co., 329 U.S. 637,
647-48 (1947) (noting the potential for pro-competitive uses of grantbacks, and
refusing to find them illegal per se).
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incentive to innovate. 10 These characteristics of grantbacksand thus their appropriate treatment under antitrust lawdon't change depending on the validity or scope of the patents
in question.
D. PRICE-, OUTPUT-, OR TERRITORY-RESTRICTED LICENSES OR
CROSS-LICENSES; LICENSES CONTAINING FIELD-OF-USE
RESTRICTIONS

IP settlement agreements among competitors that set
prices, limit output, or divide markets deserve close antitrust
scrutiny.1 11 In the absence of any integration of production, all
three of these practices are "naked" restraints and would be per
se unlawful absent the license agreement. By contrast, most
licenses that limit output or divide markets are lawful if the
underlying IP rights are valid and infringed, since the owner of
a valid IP right would have the right to prevent the licensee
from selling into this market at all. 1 2 In addition, a narrow
subset of price-restricted licenses are also valid, provided that
they qualify for the GE exception. 113
The situations described in Part IV.A above involved
settlements that gave the infringement defendant an
unrestricted right, whether exclusive or non-exclusive, to
employ the infringement defendant's technology.
Such
agreements are generally competitively harmless because they
do not limit the number of units of output that can be produced
under the settlement. Of course, the parties could surreptitiously fix prices or divide markets aside from their

110. 1 HOVENKAMP ET AL., supra note 3, § 25.3; ANTITRUST GUIDELINES,
supra note 21, § 5.6, http://www.usdoj.gov/atr/public/guidelines/ipguide.pdf.

111. See United States v. New Wrinkle, Inc., 342 U.S. 371, 380 (1952)
(declaring cross-licensing with price restrictions unlawful per se); HartfordEmpire Co. v. United States, 323 U.S. 386, 430-32 (1945) (condemning
horizontal customer and price restrictions); United States v. Masonite Corp.,
316 U.S. 265, 276 (1942) (condemning cross-licensing with price restrictions);
United States v. Gen. Elec. Co., 272 U.S. 476, 494 (1926) (finding immunity for
a price-fixing agreement that was contained in a patent license); Bement v.
Nat'l Harrow Co., 186 U.S. 70, 95 (1902) (same); United States v. Huck Mfg.
Co., 227 F. Supp. 791, 805 (E.D. Mich. 1964), affd by an equally divided Court,
382 U.S. 197 (1965).
112. This once again assumes the absence of noninfringing substitutes. If
a licensee could have produced a noninfringing substitute, but chose instead to
enter into an arrangement with the patentee to divide markets, cartel
concerns are heightened.
113. See supra notes 30-35 and accompanying text (discussing the GE
exception).
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settlement agreement, but such an agreement could be
separately considered under the antitrust laws.
By contrast, price- and output-restricted licenses create
clear competitive harms.
Those competitive harms are
tolerable if-but only if-they are part of the supracompetitive
return the government has granted to an IP owner under a
social policy designed to encourage innovation. IP law requires
that we tolerate departures from a competitive marketplace,
but only where legitimate IP rights in fact exist and are
infringed. The particular problem of the GE doctrine-and the
reason the government and most commentators have criticized
it-is that it gives antitrust immunity to naked price-fixing
when couched in the guise of an IP licensing agreement.1 14 As
the general antitrust literature on exclusionary strategy makes
clear, cooperating is frequently much more profitable than
competing. 15 As long as the GE rule remains the law, pricefixing, in at least a limited range of patent licenses, must be
tolerated; but it never needs to be tolerated when the disputed
patent claims are unenforceable.
The Patent Act expressly authorizes territory-restricted
licenses.1 16 It has also been interpreted to authorize most fieldof-use restrictions, which are the equivalent of customer and
product restraints. 117 The same thing is generally true of
production limits, because inherent in the concept of a license is
the right to license a specified amount. 1 8 Once again, however,
these are restrictions imposed as part of a social policy
designed to grant certain powers to owners of valid patent
See 2 HOVENKAMPETAL., supra note 3, §§ 31.4, 31.6.
115. See, e.g., HOVENKAMP, supra note 17, § 8.8 (noting, in the predatory
pricing context, that the most rational strategy for a dominant firm and its
rivals may be collusion rather than fighting until the market produces either
monopoly or competition).
116. 35 U.S.C. § 261 (2000).
117. Gen. Talking Pictures Corp. v. W. Elec. Co., 304 U.S. 175, 181 (1938),
affd on reh'g, 305 U.S. 124, 127 (1938); B. Braun Med. v. Abbott Labs., 124
F.3d 1419, 1429 (Fed. Cir. 1997).
118. E.g., Atari Games Corp. v. Nintendo of Am., Inc., 897 F.2d 1572, 1578
(Fed. Cir. 1990) (upholding quantity limitations on game cartridges
manufactured under a patent license); Texas Instruments, Inc. v. Hyundai
Elecs. Indus., Co., 49 F. Supp. 2d 893, 915 (E.D. Tex. 1999) (upholding a
license agreement under which TI licensed Hyundai to produce a specified
dollar value of product). The rule permitting licenses of a specified amount is
old, antedating the antitrust laws. See Aspinwall Mfg. Co. v. Gill, 32 F. 697,
698-99 (C.C.D.N.J. 1887) (finding that a licensee who was licensed to make
100 patented potato planters but who made 125 was guilty of infringement as
to the excess).
114.
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claims within the scope of those claims. If a patent is invalid or
if a licensee's technology does not infringe in the first place, a
geographic or customer-based restriction by agreement among
competitors is nothing more than a naked market division
agreement.
Even a "naked" horizontal market division agreement is
competitively harmless, however, if it occurs in a competitive
market in which the defendants are merely a few among
several significant players, or if the restraint does not suggest a
significant potential for reducing market-wide output.
Consider the Clorox decision, which involved a settlement of a
trademark dispute.' 19 The parties were the owners of the
"Pine-Sol" and "Lysol" trademarks for various household
cleaners, disinfectants, and deodorizers. 120 The owner of the
first-filed "Lysol" mark had alleged many years earlier that the
"Pine-Sol" name was misleadingly similar to its own. 121 After
pursuing litigation for a time, the parties settled their dispute
by an agreement that restricted the way in which products
bearing the name "Pine-Sol" could be advertised and the types
of household products that could be sold under the "Pine-Sol"
name. 122
Such an agreement would have been a per se unlawful
horizontal market division in the absence of the trademark
dispute. 123 Further, one might question whether the "Pine-Sol"
name really was confusingly similar to the older "Lysol"
124
name-that is, whether the trademark was infringed.
Nevertheless, rather than pursue further litigation, the parties
worked out an agreement that permitted use of the "Pine-Sol"
name, provided that it were used only with a restricted list of
125
products that contained pine oil as an active ingredient.
119. Clorox Co. v. Sterling Winthrop, Inc., 117 F.3d 50, 52 (2d Cir. 1997).
120. Id.
121.

Id.

122. Id.
123. See, e.g., Blackburn v. Sweeney, 53 F.3d 825, 830 (7th Cir. 1995)
(holding a horizontal agreement limiting advertising in one another's areas
per se unlawful).
124. A trademark examiner had once denied registration of the "Pine-Sol"
name because of presumed similarity. Clorox, 117 F.3d at 53. The examiner's
conclusions were somewhat dubious, however. He reasoned that because one
could slur the word "Pine-Sol" into "Pi-Sol," it could be stated in such a fashion
as to sound too much like "Lysol." See id.
125. Id. Over the next twenty years, further controversy erupted and this
agreement was modified from time to time. Id. The current owner of the
Pine-Sol name, who wished to market a new product in conflict with the

20031

ANTICOMPETITIVE SETTLEMENT

1749

Some other factors are relevant as well. First, as the court
pointed out, the agreement was not literally a horizontal
market division at all: It did not regulate Clorox's right to make
or market any product. 126 It merely "regulate[d] the way a
competitor [could] use a competing mark." 127 Further, having
found a bona fide dispute and what appeared to be a reasonable
attempt to settle it, the court applied the rule of reason and
dismissed the complaint for lack of any showing of harm to
competition.' 28 The strength of that conclusion would depend
on the proliferation of other brands of the cleansers and
household chemicals at issue, the height of entry barriers, and
the ease with which the firms could expand their business
129
under different trademarks.
In short, price- and output-restricted licenses are generally
illegal in the absence of a valid IP right, but generally legal
where such a right exists. Sometimes-as in the Clorox casethe nature of the agreement will suggest that harm to
competition is unlikely even if the IP right is not infringed. But
in other cases involving territorial or field-of-use restrictions,
the merits of the IP dispute will determine the outcome of the
antitrust claim.

E. PAYMENTS TO INFRINGEMENT DEFENDANTS; HATCHWAXMAN SETTLEMENTS

Insofar as antitrust is concerned, among the most
problematic settlement agreements are those in which the
infringement plaintiff pays the infringement defendant for the
latter's abandonment 3of the market (what we call here an
"exclusion payment"). 0 To illustrate, suppose that a widget
existing settlement agreement, brought the present case. Id. at 54.
126. Id. at 57.
127. Id. at 55-56.
The court's conclusion is correct, but at least
superficially inconsistent with the Supreme Court's decision in United States
v. Topco Associates, which applied the per se rule and struck down horizontal
agreements restricting where the owners of valid, uncontested marks could
use them. 405 U.S. 596, 608 (1972); see also United States v. Sealy, Inc., 388
U.S. 350, 357-58 (1967) (applying the per se rule to an agreement that forbade
manufacturers from making bedding bearing "Sealy" trademarks in one
another's territories, but left them free to manufacture bedding bearing other
labels); 12 HOVENKAMP, supra note 7, $ 2030c.
128. Clorox, 117 F.3d at 60.
129. Id. at 56-57. For a discussion of the role of market power in the rule of
reason, see 2A AREEDA ET AL., ANTITRUST LAW 1 501-508 (1995).
130. See e.g., In re Terazosin Hydrochloride Antitrust Litigation, 164 F.
Supp. 2d 1340, 1343 (S.D. Fla. 2000). When Zenith and Geneva each began
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patentee observes incipient competition from a rival producer
and files an infringement action. This lawsuit could be settled
by (1) the infringement defendant's purchase of an exclusive or
non-exclusive license from the patentee, followed by the
defendant's production under the license, or (2) the
infringement plaintiffs purchase of an agreement from the
defendant that it abandon its entry plans. Alternative (1)
brings a new rival into the market. It can facilitate competitive
production, depending on whether the license is price- or
quantity-restricted. It can also encourage further innovation in
the market by giving two companies an incentive to improve on
the widget. By contrast, alternative (2) keeps the rival out of
the market and induces it to drop its suit in exchange for a
payment.
Thus, there are competitive reasons to favor
inclusive rather than exclusive settlements.
In a perfectly functioning market without transaction
costs, a monopoly producer would be indifferent between
producing everything itself and simply "licensing" another to
make part of its production. The license fee would be the
monopoly markup, output would remain at the monopoly level
as it would in any perfect cartel agreement, and the monopolist
would earn the same profits, although part of them would be
paid as license fees rather than as markup on goods that it
produced.
If all parties were completely certain that a patent was
valid and infringed, a patentee would have precisely the same
set of incentives. It would either produce all output under the
patent itself, or else it would license some output to a rival,
earning the monopoly profits as royalties."' Assuming zero
programs to produce a generic equivalent of a pharmaceutical patented by
Abbott, Abbott claimed infringement. Id. at 1344. It settled both suits, paying
Zenith $3 million and Geneva $4.5 million each month for their promise to
stay out of the market. Id. at 1346. The district court's finding of per se
illegality is currently on appeal to the Eleventh Circuit. See also In re
Cardizem CD Antitrust Litigation, 105 F. Supp. 2d 682, 706-07 (E.D. Mich.
2000) (finding per se illegality on facts similar to Terazosin).
We intend the term "exclusion payment" to include situations in which the
defendant, often a generic pharmaceutical company, never has an opportunity
to enter the market, and is paid not to enter, as well as situations in which the
defendant is paid to exit a market in which it already competes.
131. Cf. Intel Corp. v. U.S. Int'l Trade Comm'n, 946 F.2d 821, 826 (Fed.
Cir. 1991) (involving Intel, which owned a patent on a processor chip but hired
Sanyo as its "foundry," or "subcontractor," to produce chips under its license).
Uncertainty about the outcome of an infringement suit might also incline
the patentee to settle, either by accepting a royalty in exchange for a license or
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transaction costs, however, a firm in that position would have
no incentive whatsoever to pay another firm to stay out of the
market. It could exclude without paying anything at all. This
fact undoubtedly explains why the great majority of licensing
agreements involve licenses given to the infringement
defendant contemplating actual production, and not exclusion
payments. The exclusion payment necessarily reduces the
patentee's surplus; the license reduces the surplus only if the
licensee fee extracts less than the full monopoly rent from the
licensee.
Transaction costs change the picture somewhat.
If
bringing and winning an infringement suit costs $1 million, the
patentee might be willing to pay the infringement defendant up
to that much because the cost 132
of the settlement would be lower
than the cost of an injunction.
1. Overview of Hatch-Waxman Provisions
Conceptually, the problem of exclusion payments can arise
whenever the patentee has an incentive to postpone
determination of the validity of its patent. Practically, the
problem of exclusion payments has arisen in antitrust law
primarily in the pharmaceutical industry because of its unique
patent rules. The 1984 Hatch-Waxman legislation attempted
to balance the pioneer drug manufacturers' innovation
incentives against the need to facilitate market entry by
manufacturers of equivalent generic products.133 Because these
else by making a payment in exchange for the infringement defendant's exit.
Under perfect information, the differences between the two types of
agreements tend to dissolve. For example, suppose that a patent is worth $1
million per year as long as it excludes everyone, and there is a 60% chance
that the infringement claim will prevail. In that case the patentee would be
willing to pay some amount up to the present value of $400,000 per year to
obtain an agreement from the infringement defendant that it not enter the
market. The patentee could obtain precisely the same value by a license
agreement given to the infringement defendant whose value makes the joint
production of the two firms worth $600,000 a year to the patentee. In either
case the patentee would obtain its expected value of $600,000 a year from the
patent. Litigation costs and market uncertainties would certainly complicate
the calculus, but they would not change the basic principle.
132. Of course, the settlement would not resolve questions about the
patent's validity or coverage while the court's judgment would, making the
settlement less valuable.
133. See Drug Price Competition and Patent Term Restoration (HatchWaxman) Act, Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended in
scattered sections of 15, 21, 28, and 35 U.S.C.). Tom Cotter has an excellent
discussion of the details of Hatch-Waxman. See Thomas F. Cotter, Refining
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concerns lay jointly in the domains of both the patent law and
the law that governs FDA approval of new drug products, the
Hatch-Waxman legislation included an extensive series34 of
amendments to both the patent and federal drug statutes.1
A major focal point of Hatch-Waxman was the prompt
resolution of patent infringement disputes between pioneers
and potential generic entrants. 35 Hatch-Waxman introduced
three pertinent innovations: (1) a patent "listing" requirement
directed to the pioneer, 36 (2) a thirty-month stay of the FDA's
approval of the generic product whenever a patentee sues an
infringer, 37 and (3) a 180-day exclusivity period benefiting the
first generic producer to enter the market once a patent
expires. 38 Each of these affects the bargaining dynamic in
modern pioneer/generic pharmaceutical patent litigation, and
each can be criticized as presenting opportunities for either
unilateral anticompetitive behavior on the part of the pioneer
or pioneer/generic collusion in the form of anticompetitive
settlements.
When a pioneer drug manufacturer seeks FDA approval for
a new product by filing a New Drug Application (NDA), the
pioneer must list any patents having product or method-of-use
claims that would be infringed by a generic producer. 39 Listing
provides notice to potential generic producers, but it also
presents pioneers with an opportunity to force a series of
downstream consequences having the potential to hinder
competition. Collateral disputes have now arisen over the

the "Presumptive Illegality" Approach to Settlements of Patent Disputes

Involving Reverse Payments: A Commentary on Hovenkamp, Janis & Lemley,
87 MINN. L. REV. 1789 (2003); see also Marcy Lobanoff, Comment, AntiCompetitive Agreements Cloaked as "Settlements" Thwart the Purposes of the
Hatch-Waxman Act, 50 EMORY L.J. 1331, 1332-37 (2001).

134. See §§ 101-105, 98 Stat. at 1585-1603.
135. See 21 U.S.C. § 355(j)(5) (2000).
136. See id. § 355(b)(2)(a).
137. See id. § 355(j)(B)(iii).
138. See id. § 355(j)(B)(iv).
139. NDA applicants must file
the patent number and expiration date of any patent which claims
the drug for which the applicant submitted the application or which
claims the method of using such drug and with respect to which a
claim of patent infringement could reasonably be asserted if a person
not licensed by the owner engaged in the manufacture, use, or sale of
the drug.
Id. § 355(b)(1). The FDA publishes this information in the so-called "Orange
Book." See id. § 355(j)(7)(A)(iii).
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"listability" of particular patents or types of patent claims. 40
One of the key downstream consequences of a patent
listing in a pioneer's NDA is the prospect that FDA approval of
a competitor's generic product will be stayed for thirty
months. 14 1 A potential entrant into the generic market can
secure FDA approval by filing an Abbreviated New Drug
Application (ANDA), which asserts that the generic product is a
bioequivalent of the pioneer product. 142 Where the pioneer's
product or method of use is the subject of patent protection, and
the pioneer has listed the patents, the generic's ANDA must
also include one of four certifications concerning the impact of
the pioneer's listed patents on the generic's proposed
manufacturing activity. 4 3 Of greatest relevance here is. the
Paragraph IV certification, under which the ANDA applicant
44
asserts that the relevant patent is invalid or not infringed
and provides a detailed notice (known as "2(B)(i) notice") to the
pioneer, including a detailed opinion supporting the assertions
of invalidity or noninfringement.145
When the generic makes a Paragraph IV certification, the
pioneer has forty-five days from the date of the 2(B)(i) notice to
sue for infringement. 146 If the pioneer does not timely file such
a suit, the ANDA approval "shall be made effective
immediately." 4 7 If the pioneer does timely file, ANDA approval
is effective "upon the expiration of the thirty-month period"
beginning on the date of receipt of the (2)(B)(i) notice, although
the court may order a shorter or longer period where "either
party to the action failed to reasonably cooperate in expediting
the action." 4 8 If a court concludes in a final decision that the
patent is invalid or not infringed prior to the expiration of the
140. See, e.g., Mylan Pharms., Inc. v. Thompson, 268 F.3d 1323, 1328-33
(Fed. Cir. 2001). In Mylan, a generic drug applicant sought to delist a patent

from the Orange Book. Id. at 1325. The court denied the request, however,
finding no such cause of action exists "outside a properly filed patent case."
Id. at 1331-33.
141. See 21 U.S.C. § 355(j)(5)(B)(iii).

142. Id. § 355(j)(2)(A)(iv).
143. Id. § 355(j)(2)(A)(vii).
144.
145.

Id. § 355(j)(2)(A)(vii)(IV).
Id. § 3550)(2)(B)(i)-(ii); see also 21 C.F.R. §§ 314.50(i), 314.94(a)(12)

(2002) (describing requirements for patent certifications by ANDA filers).
146.

21 U.S.C. § 355(j)(5)(B)(iii). The filing of an ANDA "for a drug claimed

in a patent or the use of which is claimed in a patent" is a technical act of
infringement under the patent statute. 35 U.S.C. § 271(e)(2)(A) (2000).
147. 21 U.S.C. § 355(j)(5)(B)(iii).
148. Id.

1754

MINNESOTA LAW REVIEW

[Vol 87:1719

thirty-month stay, ANDA
approval is effective as of the date of
49
that court decision.1
The existence of a single thirty-month stay materially
affects the bargaining calculus between pioneer and generic in
a patent infringement suit because it is the equivalent of an
automatic preliminary injunction that courts would be
reluctant to issue in a normal patent suit. Further, existing
law under the Hatch-Waxman provisions creates the potential
for a pioneer to invoke multiple thirty-month stays, by
successively listing new patent information in the Orange Book
relevant to a given drug product.150 The prospect of multiple
thirty-month stays presents an opportunity for anticompetitive
behavior that does not exist in ordinary patent infringement
litigation.
The final Hatch-Waxman innovation of relevance herethe 180-day exclusivity period-also may make pioneer/generic
pharmaceutical patent settlements fundamentally different
from other patent infringement settlements. 15 1 Under the
Hatch-Waxman legislation, after a first generic producer files
an ANDA containing a Paragraph IV certification, subsequent
ANDAs filed by other generic producers for the same drug
product "shall be made effective not earlier than" 180 days
after (1) the date on which the first generic begins marketing
the generic product, 52 or (2) the date of a court decision holding
the patent invalid or not infringed, whichever is earlier. 153
149.

Id. § 355(j)(5)(B)(iii)(I).

150.

The potential for multiple stays arises because multiple different

patents might cover various aspects of a single commercial drug product. The
pioneer might list a first patent, subsequently sue an ANDA filer, and trigger
a thirty-month stay of the ANDA. If the pioneer then lists new patent
information, the cycle may be started again: The ANDA filer would be
compelled to make another certification, the pioneer could sue, and the FDA
would initiate another thirty-month stay.
151. See Drug Price Competition and Patent Term Restoration (HatchWaxman) Act, Pub. L. No. 98-417, § 101, 98 Stat. 1585, 1589 (1984) (codified
as amended at 21 U.S.C. § 355(j)(5)(B)(iv)).
152. 21 U.S.C. § 355(j)(5)(B)(iv). More precisely, this is the date on which
the Secretary of Health and Human Services receives notice of the first
commercial marketing of the generic drug under the first generic's ANDA. Id.
153. Id. Before 2000, the FDA regulations provided that a court decision
triggered the 180-day exclusivity period only if the decision was a "final
judgment from which no appeal can be or has been taken." 21 C.F.R.
§ 314.107(e)(1) (1999). In response to Mylan Pharmaceuticals,Inc. v. Shalala,
81 F. Supp. 2d 30 (D.D.C. 2000), the FDA now considers the decision of a
district court to trigger the 180-day period. Guidance for Industry on Court
Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-
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Until 1998, the FDA conditioned the 180-day market
exclusivity period on the requirement that the first generic
ANDA filer have successfully defended against a patent
infringement suit. 154 In Mova PharmaceuticalCorp. v. Shalala,

the D.C. Circuit struck down this practice. 15 5 The FDA now
grants the exclusivity period* to the first generic ANDA filer
whether or not the pioneer has sued the generic for patent
infringement. 156
It is widely understood that the 180-day exclusivity period
offers the potential for collusive settlement arrangements
between pioneers and generics. A pioneer could initiate a
patent infringement suit against a first generic ANDA filer and
settle the litigation with a "non-entry" payment to the generic,
under which the generic would delay commercialization of the
generic product, thus postponing the commencement of the
180-day exclusivity period and locking other generics out of the
157
market indefinitely.
According to a recent FTC study, out of twenty final
settlement agreements resolving patent litigation between
pioneers and first generic ANDA filers, fourteen contained
waiting period provisions-i.e., provisions mandating that the
generic wait for a specified period of time, ending on or before
58
the date the patent expired, before entering the market.

Waxman Amendments to the Federal Food, Drug, and Cosmetic Act;
Availability, 65 Fed. Reg. 16,922, 16,922-23 (Mar. 23, 2000) (specifying that
the new rules apply only to ANDAs containing paragraph IV certifications
filed after March 30, 2000).
154. 21 C.F.R. § 314.107(c)(1).
155. 140 F.3d 1060, 1066-74 (D.C. Cir. 1998).
156. Guidance for Industry on 180-Day Generic Drug Exclusivity Under
the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic
Act; Availability, 63 Fed. Reg. 37,890, 37,890-91 (July 13, 1998). Proposed
regulations implementing this approach are still pending. See 180-Day
Generic Drug Exclusivity for Abbreviated New Drug Applications, 64 Fed.
Reg. 42,873, 42,874 (Aug. 6, 1999).
For
157. Other agreements are even more clearly anticompetitive.
example, an agreement by a patentee and a potential generic entrant that the
patentee will pay the generic to continue the lawsuit-and thus the automatic
stay of any generic entry-without ever prosecuting it to a conclusion is clearly
anticompetitive and lacks even the redeeming virtue of ending an expensive
litigation. Such an agreement can be condemned as illegal per se. Cf. Cotter,
supra note 133, at 1800 (noting that many of the Hatch-Waxman cases had
such other anticompetitive features in addition to exclusion payments).
158. FED. TRADE COMM'N, GENERIC DRUG ENTRY PRIOR TO PATENT
EXPIRATION: AN FTC STUDY 26 (2002), http://www.ftc.gov/os/2002/07/
genericdrugstudy.pdf.
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Nine of the agreements studied by the FTC involved payments
from the pioneer to the generic. 159 Payments under the nine
0
agreements ranged from $1.75 million to $132.5 million total.16
2. Solutions to the Problem of Pharmaceutical Settlements
To the extent that Hatch-Waxman provisions present
opportunities for anticompetitive settlements, antitrust law is
not the only potential recourse, nor is it necessarily the desired
one. An array of other legislative and regulatory proposals
161
have been considered or are under current consideration.
For example, one legislative proposal would have eliminated
the thirty-month stay provisions and would have limited
exploitation of the 180-day exclusivity period by requiring the
first generic ANDA filer to market a product within ninety days
after resolution of a patent infringement suit, or risk having
the 180-day exclusivity period roll over to the next generic
ANDA filer. 6 2 Recent proposed FDA regulations would take a
slightly different tack. 163 The new regulatory package would
forbid the grant of more than one thirty-month stay for any
given ANDA filing, and would implement restrictions on
pioneers' patent listing practices in NDAs. 164 Although these
proposals may go some distance toward altering the incentives

159. Id. at 25, http://www.ftc.gov/os/2002/O7/genericdrugstudy.pdf.
160. Id. at 31-32, http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf.
Although the sheer amount of the payment alone may seem sufficient to raise
concerns about potential anticompetitive behavior, additional information
would seem relevant as well-for example, the length of time over which the
payout is being made (typically measured by the time between the agreement
and patent expiration) and the value of the brand name product (measured,
for example, in terms of the pioneer's net sales of the product annually). The
FTC study includes such information for each of the nine agreements. Id.,
http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf
161. For a discussion of these proposals, see Julia Rosenthal, HatchWaxman Use or Abuse? Collusive Settlements Between Brand-Name and
Generic Drug Manufacturers,17 BERKELEY TECH. L.J. 317, 331-34 (2002).
162. S. 812, 107th Cong. §§ 5, 6 (2002). For an argument in support of
eliminating the thirty-month stay provisions, see Lemley, supra note 1, at
1529-30.
163. See Applications for FDA Approval to Market a New Drug: Patent
Listing Requirements and Application of 30-Month Stays on Approval of
Abbreviated New Drug Applications Certifying that a Patent Claiming a Drug
Is Invalid or Will Not Be Infringed, 67 Fed. Reg. 65,448, 65,449-56 (Oct. 24,
2002). Regarding the rationale for restricting grants of thirty-month stays,
see id. at 65,455-56. Regarding changes to listing practices, see id. at 65,44953.
164. Id. at 65,449-53, 65,455-56.

20031

ANTICOMPETITIVE SETTLEMENT

1757

for pioneers and generics to collude in settling patent
infringement suits, we expect that antitrust rules will continue
to be important in Hatch-Waxman matters. 165
In the
paragraphs that follow, we suggest how we believe antitrust
should treat exclusion payments.
Exclusion payments were not common in patent
infringement litigation prior to the passage of the HatchWaxman amendments. 166 Undoubtedly, what has increased
their attraction under that statute is the fact-unique to
pharmaceutical patents-that a properly defined settlementplus-exit-payment keeps not only the immediate infringement
defendant out of the market for a time, but also keeps other
167
generic firms from entering as well.
In the typical Hatch-Waxman case involving a large
exclusion payment, the rule of reason will not be a fruitful
avenue of inquiry. The very fact that the pioneer finds it
worthwhile to pay a large exclusion payment tends to establish
market power. 168 It also suggests some inherent uncertainty as
165. Some legislative proposals reflect this sentiment. For example, one
legislative proposal would facilitate antitrust scrutiny by requiring that
Hatch-Waxman settlements be disclosed to the antitrust agencies. S. 754,
107th Cong., § 5 (2002).
166. See Cotter, supra note 133, at 1798 n.43 (2003). For a discussion of
rare instances of such payments, see Robert J. Hoerner, Antitrust Pitfalls in
Patent Litigation Settlement Agreements, 8 FED. CIR. B.J. 113, 121-23 (1998).
In cross-licenses, of course, net payments could go from one party to
another depending on the relative value of the patents each licensor holds.
But, where only one party owns a patent, it is virtually unheard of outside of
pharmaceuticals for that party to pay an accused infringer to settle the
lawsuit. Cf M. Howard Morse, Settlement of Intellectual Property Disputes in
the Pharmaceuticaland Medical Device Industries:Antitrust Rules, 10 GEO.
MASON L. REV. 359, 362 (2002) (noting that pharmaceutical settlements may
sometimes include "side deals" justifying such a payment).
167. Hatch-Waxman also changes the general economic analysis of the
costs and benefits of litigation. Because the law provides for an automatic
stay of entry by generic manufacturers once the pharmaceutical patentee files
suit, patentees do not lose profits and defendants do not gain profits unless
and until the patent is determined to be invalid or non-infringed. Compare
Cotter, supra note 133, at 1800-01, with id. at 1802-05 (discussing how this
affects the settlement calculus).
168. For example, a pioneer's willingness to pay 10% of its profits as an
exclusion payment to a generic rival suggests that the pioneer's profitmaximizing price is at least 10% above its costs. That market power may well
have been legally conferred by an IP right, but the validity of that right is the
very subject at issue in a settlement case.
It is also no answer to say that judges lack significant experience with
exclusion payments, and as a result these should be governed by the full rule
of reason. See Morse, supra note 166, at 361-62 (arguing for a rule of reason
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to the validity or scope of the patent; as noted above, a patentee
that is certain of winning will not pay anything more than its
anticipated remaining legal. fees in exchange for an agreement
by a generic to exit the market. 169 The very fact of that
uncertainty
suggests
that
exclusion
payments
are
anticompetitive-that on average such agreements exclude at
least some generics that in fact had a legal right to compete.
In his contribution to this Symposium, Tom Cotter
acknowledges the antitrust risks to exclusion payments. 170 He
argues, however, that it will often be rational for
pharmaceutical patentees to agree to make exclusion payments
to generic competitors, and therefore that the mere existence
and size of those payments should not automatically incline
courts to find that they are illegal.' 7' We do not think it follows
that because it is rational for the patentee to agree to an
exclusion payment, that payment cannot be anticompetitive.
72
Far from it. Breaking down the equations in Cotter's model
makes it clear that there are two components of any rational
exclusion payment. The first is the cost of continued litigation.
Even a patentee sure to win would be willing to pay a
defendant a sum up to the cost of the lawsuit to end the
litigation and avoid that cost. The second, more significant
number is the value of eliminating competition that the
patentee could not expect ex ante to exclude after trial. A close
look at Cotter's model confirms that the size of the expected
exclusion payments are inversely related to the strength of the
patentee's case: the less likely the patentee is to win, the more
it is willing to pay a generic to stay out of the market. 73 Thus,
approach in most cases). Consider, for example, In re Schering-Plough Corp.,
in which the ALJ applied the rule of reason because judges lacked experience

with Hatch-Waxman-style exclusion payments and dismissed the complaint.
See No. 9297, slip op. at 98 (June 27, 2002) (initial decision), available at
http://www.ftc.gov/os/2002/07/scheringinitialdecisionp2.pdf.
The "judicial
experience" argument runs to classes of restraints, not to particular products.
An exclusion payment is in fact a type of naked horizontal market division
agreement, and naked market division agreements have been unlawful for a
long time. For example, if a group of skateboard manufacturers should fix

prices, one would not say that judicial experience with price-fixing in
skateboards is very limited, so the rule of reason should be applied.
169. See, e.g., Shapiro, supra note 23 (manuscript at 35, on file with
authors); Cotter, supra note 133, at 1806 tbl.1.
170. Cotter, supra note 133, at 1805-07.

171. Id. at 1808-11.
172. See id. at 1806.
173. Id. at 1808-09.

Crane acknowledges this, though curiously he
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if the patentee is sure to win, the second number is zero and
74
the exclusion payment is no more than the cost of litigation.1
But if the patentee has a 25% chance of losing, it is willing to
pay up to 25% of the value of its monopoly to exclude its
competitors without a trial. 75 The reason the patentee is
willing to make this payment is precisely because the
settlement will permit it to exclude competition from the
market, whereas if it went to trial there is a 25% chance that
the patent would be held invalid or not infringed and the
market would become competitive.
Far from justifying
exclusion payments on competitive grounds, therefore, Cotter's
model demonstrates that those payments are inherently
anticompetitive. On expectation, the patentee is paying for an
76
advantage that it could not get if it went to trial. 1
We suggest the following rule. In an antitrust challenge, a
payment from a patentee to an infringement defendant for the
latter's exit from the market is presumptively unlawful,
shifting the burden of proof to the infringement plaintiff. The
infringement plaintiff can defend by showing both (1) that the
ex ante likelihood of prevailing in its infringement lawsuit is
significant, and (2) that the size of the payment is no more than
the expected value of litigation and collateral costs attending
the lawsuit. 77 The rationale for limiting exclusion payments to
considers it a virtue rather than a problem with exclusion payments. Crane,
supra note 2, at 774 ("The 'directional flow' of the settlement payment,
therefore, will be affected by the probability of the plaintiff's lawsuit

succeeding.").
174. See Cotter, supra note 133, at 1806 tbl.1.
175. See id.
176. Cf.George L. Priest, Cartels and Patent License Arrangements, 20 J.
L. & ECON. 309, 327 (1977) (arguing that rational patentees won't reduce the

royalty below zero unless they are cartelizing an industry). It is true, of
course, that some patents that go to trial will be held valid and infringed, and
therefore the patentee will keep its monopoly. But the anticompetitive harm
comes from the fact that the settlement forecloses the incremental chance that
the market would be competitive. Significantly, it is this very foreclosure that
makes exclusion payments greater than the cost of litigation rational.
177. See Blair & Cotter, supra note 26, at 534-38 (proposing a "quick look"

roughly comparable to ours); cf. Crane, supra note 2, at 779-96 (arguing that
antitrust should permit such settlements when the ex ante success of the
patent infringement suit is high, and prohibit them when the ex ante success
is low). At the same time, however, other things being equal, the higher the
objectively measured ex ante success of the infringement suit, the less the
expected size of the payment to the infringement defendant. Id. at 780-82.
For example, if the patentee was 100% sure of victory in the patent

infringement suit, a settlement payment would not exceed the amount of
expected litigation costs. See id. Thus, we think it reasonable to require both
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litigation costs is noted above. 178 In addition, we think it
important that the court make at least some limited inquiry
into the merits of a settlement that requires the defendant to
exit the market. If exclusion payments are illegal, the parties
will have an incentive to conceal those payments, perhaps by
turning them into non-cash compensation (the patentee's
forbearance from price competition in a separate market, for
example). If the patent lawsuit is a sham, and the accused
infringer still agrees to leave the market without a substantial
exclusion payment, it is worth making sure there isn't another
payment hidden in the transaction. This oversight necessarily
requires some inquiry into the merits of the IP suit, but we
think it need not be particularly searching. 179 The goal is
merely to ensure that there is a legitimate dispute being
settled.
In assessing such payments, it is important to keep in
mind that the ex ante effect of a harsh rule will not necessarily
impede settlement; it may simply make the settlement take on
a different form. For example, suppose the law absolutely
forbade a patentee from paying an infringement defendant for
its agreement not to practice technology covered by the patent.
The result may make a settlement more difficult to achieve, but
it could just as easily change the course of the settlement-for
example, to one in which the infringement defendant obtains a
license from the patentee. Since such a settlement permits
proof of likely success on the merits and, because it is evidentiary of likely
outcomes, proof that the payment to the accused infringer did not exceed the
patentee's expected litigation costs. Although Cotter is critical of our proposed
limit on the size of exclusion payments, he is in general agreement with our
position that they should be presumptively illegal. See Cotter, supra note 133,
at 1797-98. Unlike us, he would permit a more open-ended inquiry into how
large a payment should be permitted. See id.

The definition of litigation costs will also matter in practice. We think
they should be limited to a good faith estimate of the out-of-pocket costs and
attorney's fees the patentee could expect to pay between the time of the

settlement and the time the case was concluded. Although Robert Willig and
John Bigelow have suggested that the value of uncertainty could be included
in "litigation costs," Robert D. Willig & John P. Bigelow, Antitrust Policy
Towards Agreements that Settle Patent Litigation, 41

J.

ECON.

LIT.

(forthcoming 2003), we think this impermissibly brings in the value of certain
exclusion based on a doubtful patent under the rubric of litigation expenses.
178.

See supra notes 172-76 and accompanying text.

179.

Most of the alternatives proposed by those who favor exclusion

payments in some circumstances require a more searching inquiry into the
merits than does our proposal. See, e.g., Crane, supra note 2, at 779-96; Willig
& Bigelow, supra note 177.
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more competition while allowing the parties to avoid the costs
of uncertainty, it is preferable to a settlement based on
exclusion payments. 180 Tom Cotter derides this as akin to a
compulsory licensing rule,18 1 but in fact antitrust law is not
compelling licensing of any sort. The patentee need not license
at all. For the cost of a lawsuit, the patentee can simply
enforce its rights without any fear of antitrust liability. If the
patent is valid and infringed, the elimination of competition
that results is entirely justified by IP policy. It is only where
the patentee wants to eliminate competition through collusion
that antitrust law properly takes notice.
Nor is there any significant risk that a rule limiting
exclusion payments would reduce the legitimate value of
pharmaceutical patent rights. As Carl Shapiro has pointed out,
a patent is not a right to exclude, but rather a right to try to
exclude. 82 Indeed, a significant number of patents that make
it to court are ultimately held invalid or not infringed.183 The
legitimate exclusion value of a pharmaceutical patent is the
power it actually confers over competition, which is in turn a
function of the scope of the patent and its chance of being held
valid. 8 4 What the pharmaceutical patentees who agree to
exclusion payments seek is something more-a guaranteed
insulation from competition, without the risk that the patent is

180. Crane points out that there may be other costs to licensing some
infringers, if there is reason to believe they will somehow harm the reputation
of the patentee. Crane, supra note 2, at 767-68. This concern is plausible,
though rare. But, it doesn't justify exclusion payments. A patentee who does

not wish to license doesn't have to-it can pay the accused infringer a small
amount to settle, or it can pay an equivalent amount to litigate the case
through trial. See Cotter, supra note 133, at 1808-09.
181. See Cotter, supra note 133, at 1809-10 nn.78-79.
He concedes,
however, that the analogy is imperfect. Id. at 28 n.79.
182. Shapiro, supra note 23 (manuscript at 9, on file with authors).
183. See John R. Allison & Mark A. Lemley, Empirical Evidence on the
Validity of Litigated Patents, 26 AIPLA Q.J. 185, 205-07 (1998) (finding that
46% of patents litigated to judgment are held invalid); Kimberly A. Moore,
Judges, Juries and Patent Cases-An EmpiricalPeek Inside the Black Box, 99

MICH. L. REV. 365, 390 (2000) (finding that 33% of patents litigated to trial
are held invalid).
184. Patents have other values, too. See, e.g., Clarisa Long, Patent Signals,
69 U. CHI. L. REV. 625, 637 (2002) (arguing that patents serve as financing
signals for companies); John R. Allison et al., Valuable Patents 25-31 (2003)

(unpublished manuscript, on file with authors) (discussing the uses of patents
that aren't litigated); Paul J. Heald, A Transaction Costs Theory of Patent
Law 2 (2003) (unpublished manuscript, on file with authors) (arguing that
patents solve corporate organization problems).
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held invalid. IP policy does not offer such a guarantee, and
does not immunize from antitrust scrutiny those who seek it by
entering into agreements that exclude potential competitors.
Another alternative to exclusion payments is for the
parties to settle a patent dispute by delaying entry by the
generic. A stipulated injunction that lasts for less than the
term of the patent is more likely to reflect the uncertain
outcomes of patent litigation. For example, if a patent with ten
years of term remaining is 50% likely to be held invalid, the
parties might settle the case by agreeing that the generic will
not enter for a specified number of years, but then will be able
to enter without paying a royalty. 185 The parties have
effectively split the uncertainty costs of the litigation.186 More
important, assuming delayed entry is not coupled with an
exclusion payment, it does not align the incentives of pioneer
and generic litigants: Generics will want the delay to be as
short as possible, and patentees to make the delay as long as
possible. This means that we can expect that an agreement to
delay entry likely reflects the parties' joint assessment of the
likely outcome of the litigation. A delayed entry agreement
therefore allows the parties to capture the economic signifi187
cance of uncertainty as to patent outcome.
As a result, we think courts ordinarily should not object to
a delayed-entry settlement, because it is likely to be an
estimate of the expected outcome by the parties with the best
information about that outcome. Two caveats are necessary,
however. First, delayed entry is an efficient solution only if it
is not coupled with any form of exclusion payment. If a pioneer
pays a generic to delay entry, the likelihood is that the delay
does not in fact represent the expected outcome of litigation,
but rather has been biased toward later entry by the payment.
185.

For endorsement of such an approach as pro-competitive, see Willig &

Bigelow, supra note 177.

186. Actually, the determination of the length of the delay is a bit more
complicated than suggested in the text. First, the relevant period to be
divided should begin when the trial would end, or when the thirty-month stay
would end, whichever is earlier; the generic couldn't enter before that date
anyway. Second, because of the time value of money, the first five years of a

ten-year period will provide more than 50% of the expected return over that
period. The real calculation of the efficient delay will need to take into
account the discount rate.
187. O'Rourke and Brodley also endorse delayed entry as an alternative to
exclusion payments. See Joseph F. Brodley & Maureen A. O'Rourke, Patent
Settlement Agreements, ANTITRUST, Summer 2002, at 53, 55; O'Rourke &
Brodley, supra note 51, at 1786-87.

2003]

ANTICOMPETITIVE SETTLEMENT

1763

Second, there is always a risk that the parties will successfully
conceal an exclusion payment, for example by agreeing under
the table that the parties will cartelize the industry after entry.
To prevent this risk, courts should engage in at least some
scrutiny of delayed entry settlements to ensure that the IP
right is not a mere sham employed to conceal what is
essentially a cartel.188 This oversight necessarily requires some
inquiry into the merits of the IP suit, but we think it need not
be particularly searching. The goal is merely to ensure that
there is a legitimate dispute being settled.
F. HORIZONTAL PRICE, OUTPUT, OR MARKET DIVISION
PROVISIONS NOT COVERED BY CONTESTED IP RIGHT

Finally, and most clearly anticompetitive, are settlement
agreements in which the disputants restrain their output of
things that are not even arguably covered by the disputed IP
rights or any other, or engage in clearly unauthorized
agreements. For example, firms might settle a patent dispute
by dividing the market for products that are not covered by any
patent.
These agreements can ordinarily be condemned
without determining the validity of the IP right.
Similarly, consider a price-restricted license that clearly
goes beyond the GE exception.1 89 Although that rule exempts
price-fixing of patented goods from the Sherman Act's coverage,
the exemption does not extend to non-patented output.1 90 For
example, suppose that DuPont and Mautz, two makers of house
paint, have a dispute in which DuPont claims that Mautz is
infringing its patent for a paint mixing process. The parties
settle the dispute with an agreement in which DuPont licenses
the patent to Mautz and Mautz agrees to charge $20 per gallon
for all paint produced under the patent. This agreement, which
sets a price on the unpatented paint rather than the patented
process itself, would constitute unlawful price-fixing and is not
immunized by the GE exception.' 9 1 As a result, the court need
188.

Courts do this already in the context of patent pools and cross-license

agreements. See 2 HOVENKAMP ET AL., supra note 3, § 34.4al. O'Rourke and

Brodley worry that tests of this sort are indeterminate, O'Rourke & Brodley,
supra note 51, at 1781-82, but we don't see a good alternative.
189. Recall that the GE exception permits patent owners to control the

downstream prices their licensees charge.

See supra notes 30-35 and

accompanying text; see also 2 HOVENKAMP ET AL., supra note 3, § 31.1b.
190. United States v. Gen. Elec. Co., 272 U.S. 476, 493 (1926).
191. See United States v. Univis Lens Co. 316 U.S. 241, 253-54 (1942)

(holding that a patent on unfinished optical lens blanks did not authorize a
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not trouble itself with whether the agreement was in
settlement of a bona fide patent dispute. 192 The agreement
would be unlawful whether or not there was such a dispute.
A few of the recent cases involving pharmaceutical
193
disputes and the Hatch-Waxman Act fall into this category.
For example, In re Cardizem CD Antitrust Litigation involved a
situation in which Cardizem, the patentee of a pioneer drug,
filed an infringement suit against Andrx, a generic producer
threatening competitive entry. 194 Cardizem later settled by
paying Andrx a large sum to stay out of the market. 195 The
settlement agreement also "restrained Andrx from marketing
other bioequivalent or generic versions of Cardizem CD which
were not at issue in the pending ...patent case." 196 While the
price-fix of finished lenses ground by licensee); Ethyl Gasoline Corp. v. United
States, 309 U.S. 436, 457-61 (1940) (finding that a patent on gasoline additive
did not authorize a price-fixing license of gasoline); Cummer-Graham Co. v.
Straight Side Basket Corp., 142 F.2d 646, 647 (5th Cir. 1944) (concluding that
a patent on an attachment to a basket-making machine did not justify a pricefixing license of baskets); Am. Equip. Co. v. Tuthill Bldg. Material Co., 69 F.2d
406, 409 (7th Cir. 1934) (holding that a patent on brick loading equipment did
not justify a price-fixing license of the brick being loaded); see also United
States v. Krasnov, 143 F. Supp. 184, 198-99, 202-03 (E.D. Pa. 1956) (striking
down a cross-licensing agreement that was accompanied by price-fixing, and
suggesting that price-fixing in a cross-licensing arrangement does not enjoy
the GE exception), affd, 355 U.S. 5 (1957); United States v. Gen. Instrument
Corp., 87 F. Supp. 157, 193-97 (D.N.J. 1949) (enjoining price-fixing
accompanied by pooling); 2 HOVENKAMP ET AL., supra note 3, § 31.3b.c.
192. Indeed, in cases testing the limits of the GE rule the Supreme Court
ordinarily assumes the patent is valid. See, e.g., United States v. Line
Material Co., 333 U.S. 287, 305-10, 314-15 (1948) (assuming that the patents
in question were valid but striking down the cross-licensing agreement that
imposed resale prices on both licensees and their sub-licensees). By the same
token, once a patent expires a price-fixing agreement in its license becomes
unlawful and can no longer be enforced. See 2 HOVENKAMP ET AL., supra note
3, § 31.2f.
193. See supra Part IV.E.1 (discussing these decisions).
194. 105 F. Supp. 2d 682, 686-87 (E.D. Mich. 2000).
195. Id. at 687.
196. Id. at 697; cf. In re Terazosin Hydrochloride Antitrust Litig., 164 F.
Supp. 2d 1340, 1343-47 (S.D. Fla. 2000). In Terazosin, the infringement
defendant and incipient generic producer promised, in exchange for $6 million
per quarter, to "'not sell, offer for sale, donate, or otherwise commercially
distribute in the United States any [t]erazosin [h]ydrochloride [piroduct' until
another drug maker sold a generic version . . .in the United States." Id. at
1346 (alterations in original) (quoting the settlement agreement). This in fact
would be unlikely to occur until well after the pioneer's patent expired, so the
settlement agreement effectively contained the infringement defendant's
promise to stay out of the market even after no patent was in issue, thus
making it a per se unlawful market division.
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language in the opinion is a little opaque, if it meant that
Andrx promised not to sell products that Cardizem did not
claim in its patent to begin with, then that portion of the
agreement was per se unlawful notwithstanding the presence
of a patent dispute. The agreement was a naked horizontal
market division agreement, and the only justification for such
agreements is that market divisions such as territorial and
field-of-use restrictions are lawful when they are contained in
patent licenses.
CONCLUSION
For courts to evaluate the competitive consequences of
settlements of IP disputes, they must sometimes inquire into
the merits of those IP disputes. Because this inquiry is timeconsuming and difficult, it threatens to undo many of the
benefits of settling the dispute in the first place. As a result,
we suggest that courts endeavor to avoid this inquiry whenever
possible. They can do this in two basic ways: (1) by concluding
that the settlement does not violate the antitrust laws even if
the patents are invalid or not infringed, or (2) by concluding
that it violates the antitrust laws even if the patents are valid
and infringed. Only in a relatively small set of middle cases
will the competitive effects of a settlement depend on the
merits of the IP case. We categorize settlements in an effort to
help courts identify those cases in which a merits inquiry is
necessary.
While we have focused in this Article on
settlements of patent disputes, the same approach may be
useful in any case in which the lawfulness of a transaction
under the antitrust laws depends on the validity of an
uncertain claim to IP ownership. For example, merging parties
may claim that the merger is not anticompetitive because one
party's patent rights would have prevented competition in any
event. The tripartite framework can help cabin the inquiry into
Indeed, the problem is even worse than these cases suggest. Because
Hatch-Waxman provides that the first generic drug company to file an ANDA
is entitled to six months of generic exclusivity once the patent expires, if the
first generic agrees not to actually begin such production it can keep other
generics out of the market indefinitely. In Terazosin, the infringement
defendant also promised that it would obtain the patentee's "permission to
market such products once generic competition began." Id. Assuming that
generic competition would not begin until after expiration of the patent, this

provision of the agreement appeared to require one firm to obtain a
competitor's permission to enter when no patent was at issue-once again, a
per se unlawful market division.
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patent validity in such transactions as well.
In the middle set of cases in our taxonomy, courts and
antitrust regulators must not shy away from determining the
merits of the underlying IP claim. It is true that doing so will
raise the costs of the antitrust inquiry, and may undo some of
the cost benefits of settlement. But in the cases in which the
inquiry will occur under our taxonomy, it is because that
inquiry is the only way to determine whether a settlement is
pro- or anticompetitive. Since the Chicago revolution, antitrust
has embodied a preference for accuracy over ease. A deep
investigation of the merits of the case will sometimes be the
cost of accuracy.

